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Abstract
Pre-hospital non-invasive ventilation for acute respiratory
failure: a systematic review and cost-effectiveness evaluation
Abdullah Pandor,1 Praveen Thokala,1 Steve Goodacre,1* Edith Poku,1
John W Stevens,1 Shijie Ren,1 Anna Cantrell,1 Gavin D Perkins,2
Matt Ward3 and Jerry Penn-Ashman3
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Critical Care Medicine, University of Warwick, Coventry, UK
3West Midlands Ambulance Service NHS Foundation Trust, West Midlands, UK
*Corresponding author s.goodacre@sheffield.ac.uk
Background: Non-invasive ventilation (NIV), in the form of continuous positive airway pressure (CPAP)
or bilevel inspiratory positive airway pressure (BiPAP), is used in hospital to treat patients with acute
respiratory failure. Pre-hospital NIV may be more effective than in-hospital NIV but requires additional
ambulance service resources.
Objectives: We aimed to determine the clinical effectiveness and cost-effectiveness of pre-hospital NIV
compared with usual care for adults presenting to the emergency services with acute respiratory failure
and to identify priorities for future research.
Data sources: Fourteen electronic databases and research registers (including MEDLINE In-Process & Other
Non-Indexed Citations, MEDLINE, EMBASE, and Cumulative Index to Nursing and Allied Health Literature)
were searched from inception to August 2013, supplemented by hand-searching reference lists and
contacting experts in the field.
Review methods: We included all randomised or quasi-randomised controlled trials of pre-hospital NIV
in patients with acute respiratory failure. Methodological quality was assessed according to established
criteria. An aggregate data network meta-analysis (NMA) of mortality and intubation was used to jointly
estimate intervention effects relative to usual care. A NMA, using individual patient-level data (IPD) and
aggregate data where IPD were not available, was carried out to assess whether or not covariates were
treatment effect modifiers. A de novo economic model was developed to explore the costs and health
outcomes when pre-hospital NIV (specifically CPAP provided by paramedics) and standard care (in-hospital
NIV) were applied to a hypothetical cohort of patients with acute respiratory failure.
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Results: The literature searches identified 2284 citations. Of the 10 studies that met the inclusion criteria,
eight were randomised controlled trials and two were quasi-randomised trials (six CPAP; four BiPAP;
sample sizes 23–207 participants). IPD were available from seven trials (650 patients). The aggregate data
NMA suggested that CPAP was the most effective treatment in terms of mortality (probability= 0.989) and
intubation rate (probability= 0.639), and reduced both mortality [odds ratio (OR) 0.41, 95% credible
interval (CrI) 0.20 to 0.77] and intubation rate (OR 0.32, 95% CrI 0.17 to 0.62) compared with standard
care. The effect of BiPAP on mortality (OR 1.94, 95% CrI 0.65 to 6.14) and intubation rate (OR 0.40,
95% CrI 0.14 to 1.16) compared with standard care was uncertain. The combined IPD and aggregate data
NMA suggested that sex was a statistically significant treatment effect modifier for mortality. The economic
analysis showed that pre-hospital CPAP was more effective and more expensive than standard care, with
an incremental cost-effectiveness ratio of £20,514 per quality-adjusted life-year (QALY) and a 49.5%
probability of being cost-effective at the £20,000-per-QALY threshold. Variation in the incidence of eligible
patients had a marked impact on cost-effectiveness and the expected value of sample information for a
future randomised trial.
Limitations: The meta-analysis lacked power to detect potentially important differences in outcome
(particularly for BiPAP), the intervention was not always compared with the best alternative care
(in-hospital NIV) in the primary studies and findings may not be generalisable.
Conclusions: Pre-hospital CPAP can reduce mortality and intubation rates, but cost-effectiveness is
uncertain and the value of further randomised evaluation depends on the incidence of suitable patients.
A feasibility study is required to determine if a large pragmatic trial of clinical effectiveness and
cost-effectiveness is appropriate.
Study registration: The study is registered as PROSPERO CRD42012002933.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Bilevel positive airway pressure A system of respiratory support used during non-invasive ventilation in
which preset levels of inspiratory and expiratory positive airway pressure are applied. The pressure is higher
when a person breathes in and is lower when a person breathes out.
Continuous positive airway pressure A system of respiratory support used during non-invasive
ventilation in which a preset constant pressure is applied during inspiration and expiration.
Cost-effectiveness acceptability curve A way of illustrating cost-effectiveness results by plotting the
probability that the intervention is cost-effective (y-axis) against the maximum that society is willing to pay
for an improvement in health (x-axis).
Cost-effectiveness plane A way of illustrating cost-effectiveness results by plotting the mean incremental
cost and effectiveness on a four-quadrant graph. Interventions that are more costly and more effective fall
in the north-east quadrant.
Incremental cost-effectiveness ratio The difference in costs between one intervention and an
alternative, divided by the difference in outcomes.
Meta-analysis A statistical technique for combining (pooling) the results of a number of studies that
address the same question and report on the same outcomes to produce a summary result. The aim is to
derive more precise and clear information from a large data pool. It is generally more reliably likely to
confirm or refute a hypothesis than the individual trials.
Non-invasive ventilation A method of delivering ventilatory support through a tight-fitting mask, which
is usually applied around a person’s mouth and nose. It may take the form of continuous positive airway
pressure or bilevel inspiratory positive airway pressure.
Quality-adjusted life-year A measure of the benefit of health care that combines the impact of the
expected length of life and quality of life.
Respiratory failure A condition in which the heart and lungs fail to maintain one or both of its gas
exchange functions: oxygenation and carbon dioxide elimination. Respiratory failure can be acute (develops
within minutes or hours in patients with no, or minor, evidence of pre-existing respiratory disease), acute
on chronic (an acute deterioration in an individual with pre-existing respiratory failure) or chronic (develops
over several days, or longer, in patients with existing respiratory disease).
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List of abbreviations
3CPO Three Interventions in Cardiogenic
Pulmonary Oedema
ACPO acute cardiogenic pulmonary
oedema
BIOSIS Bioscience Information Service
BiPAP bilevel inspiratory positive
airway pressure
CEAC cost-effectiveness acceptability
curve
CI confidence interval
COPD chronic obstructive pulmonary
disease
CPAP continuous positive airway pressure
CrI credible interval
DIC deviance information criterion
EPAP expiratory positive airway pressure
EVPI expected value of perfect
information
EVPPI expected value of partial perfect
information
EVSI expected value of sample information
FiO2 fraction of inspired oxygen
HN half-normal distribution
ICER incremental cost-effectiveness ratio
IPAP inspiratory positive airway pressure
IPD individual patient-level data
JRCALC Joint Royal Colleges Ambulance
Liaison Committee
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NIV non-invasive ventilation
NMA network meta-analysis
OR odds ratio
PaCO2 arterial carbon dioxide tension
(partial pressure of carbon dioxide)
PaO2 arterial oxygen tension (partial
pressure of oxygen)
PEEP positive end-expiratory pressure
QALY quality-adjusted life-year
RCT randomised controlled trial
SpO2 oxygen saturation (as determined
by pulse oximetry)
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Plain English summary
Acute respiratory failure occurs when heart or lung disease leads to the patient being unable tomaintain oxygen levels in their blood. It can be treated with non-invasive ventilation (NIV), which
involves delivering oxygen under increased pressure through a tight-fitting face mask. There are two types
of NIV: continuous positive airway pressure (CPAP) provides constant pressure, while bilevel inspiratory
positive airway pressure (BiPAP) increases pressure as the patient breathes in. NIV (usually CPAP) provided
by paramedics in an ambulance on the way to hospital is known as pre-hospital NIV.
This study aimed to find out if pre-hospital NIV reduces the risk of a patient with acute respiratory failure
dying or needing to be put on a ventilator, and if the costs required to set up and run pre-hospital NIV are
justified by the improvements in patient health. We did this by collecting and analysing all the available
research into pre-hospital NIV and by developing a cost-effectiveness model.
We found 10 studies that showed that pre-hospital CPAP appears to reduce the risk of dying or being put
on a ventilator, while the effect of pre-hospital BiPAP is uncertain. The cost-effectiveness model showed
that providing pre-hospital CPAP would cost an ambulance service an extra £235,683–582,300 per year.
It was uncertain whether or not this represented value for money for the NHS. Cost-effectiveness
depended on the number of people who could receive, and benefit from, pre-hospital NIV each year.
More research is needed to find out how many people can receive pre-hospital NIV and how much they
benefit from it.
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Scientific summary
Background
Acute respiratory failure is a common but life-threatening medical emergency. It is caused by a number
of common cardiac or respiratory conditions, including heart failure, pneumonia and exacerbation of
chronic obstructive pulmonary disease (COPD).
Non-invasive ventilation (NIV) involves providing respiratory support through a tight-fitting mask, which is
usually applied around the patient’s mouth and nose. It may take the form of continuous positive airway
pressure (CPAP) or bilevel inspiratory positive airway pressure (BiPAP). It is usually used in hospital, but
it may be more effective if treatment is commenced prior to arrival at hospital.
Pre-hospital NIV has been evaluated in a number of trials, with the results suggesting that it reduces
mortality and intubation rates, but these trials were small and the findings were not consistent.
Implementing pre-hospital NIV would require additional training for many paramedics and additional
equipment for many ambulances. The substantial costs associated with this intervention means that robust
evidence of clinical effectiveness and cost-effectiveness is required prior to implementation.
Objectives
We aimed to determine the clinical effectiveness and cost-effectiveness of pre-hospital NIV for acute
respiratory failure and to identify priorities for future research. Our specific objectives were:
1. to undertake a systematic review, network meta-analysis (NMA) and individual patient-level data (IPD)
meta-analysis to determine the effectiveness of pre-hospital NIV
2. to develop an economic model to (a) estimate the incremental cost per quality-adjusted life-year (QALY)
gained by providing pre-hospital NIV instead of standard care; (b) estimate the additional costs incurred
by establishing and providing pre-hospital NIV, and the lives saved and QALYs gained across the
population served by a typical ambulance service; and (c) estimate the expected value of information
associated with reducing uncertainty around key parameters.
Methods
We carried out a systematic review in accordance with the general principles recommended in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We searched the
following electronic databases and research registers: MEDLINE In-Process & Other Non-Indexed Citations,
MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Cochrane Database of
Systematic Reviews, Cochrane Central Register of Controlled Trials, Health Technology Assessment
Database, Database of Abstracts of Review of Effects, Bioscience Information Service Previews, Science
Citation Index Expanded, Conference Proceedings Citation Index – Science, UK Clinical Research Network
Portfolio Database, National Research Register Archive, Current Controlled Trials and ClinicalTrials.gov.
Resources were initially searched from inception to October 2012 and then updated to August 2013. We
also checked the reference lists and undertook a citation search of relevant articles, contacted key experts
in the field and undertook systematic internet keyword searches using the Google search engine
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(Google Inc., Mountain View, CA, USA). We included randomised or quasi-randomised controlled trials
that compared pre-hospital NIV with a relevant comparator treatment in patients with acute respiratory
failure. We assessed the methodological quality of each included study according to established criteria for
randomised controlled trials (RCTs).
We conducted a NMA based on aggregate data of the number of events (i.e. mortality and intubation)
using Markov chain Monte Carlo simulation to jointly estimate the intervention effects relative to standard
care. We carried out a NMA using IPD and aggregate data where IPD were not available to assess if
covariates (i.e. age, sex, provider, primary diagnosis and severity of acute respiratory failure) were
treatment effect modifiers.
We developed a de novo economic model, using the statistical software R Version 3.0.2 (the R Foundation
for Statistical Computing, Vienna, Austria), to explore the costs and health outcomes when pre-hospital
NIV (specifically CPAP provided by paramedics) and standard care (in-hospital NIV) were applied to a
hypothetical cohort of patients with acute respiratory failure. The economic perspective of the model was
the NHS in England and Wales. The model assigned to each patient a probability of intubation or death
depending on their characteristics and whether they had pre-hospital NIV or standard care. The patients
who survived accrued lifetime QALYs and health-care costs according to their age and sex. Costs were also
accrued through costs of intervention and hospital treatment costs, which depended on patient outcomes.
The effect of pre-hospital NIV on intubation and mortality was estimated from the aggregate data
meta-analysis. Utilities were estimated from a large trial of in-hospital NIV for acute cardiogenic pulmonary
oedema (ACPO). The costs of pre-hospital NIV were estimated by calculating the total costs required for an
ambulance service to set up and run pre-hospital NIV over 5 years, divided by the number of patients
appropriately treated during this time.
We assumed that the effectiveness of pre-hospital NIV would depend on the risk of mortality from acute
respiratory failure and this would increase with the distance travelled to hospital. We therefore modelled
cost-effectiveness in general, urban and rural scenarios to reflect variation in the distance travelled
to hospital.
Cost-effectiveness was estimated in terms of the incremental cost-effectiveness ratio (ICER) of pre-hospital
NIV compared with standard care, and net monetary benefit of pre-hospital care and standard care.
Uncertainty was explored using probabilistic sensitivity analysis and the expected value of perfect
information (EVPI). We also conducted partial EVPI analysis, which evaluates the uncertainty associated
with a subset of one of more parameters, and expected value of sample information (EVSI) analysis, which
seeks to provide an optimal number of patients to study within a future trial.
Results
The literature searches identified 2284 citations. We identified and selected eight RCTs and two
quasi-randomised trials for inclusion (participant numbers ranging from 23 to 207). The authors of seven
of these 10 trials provided data from 650 patients for IPD meta-analysis.
The studies were undertaken in Australia, France, Germany, Canada and the USA and the results were
published between 2000 and 2012. Six trials were limited to patients with ACPO and two to patients with
exacerbation of COPD. Six trials evaluated CPAP and four trials evaluated BiPAP. One trial compared early
CPAP with delayed CPAP; use of in-hospital NIV in the control arm was allowed in three of the other trials,
prohibited in one and not recorded in five. The potential sources of bias most frequently identified in
studies concerned lack of blinding of outcome assessment and lack of adequate power to detect
differences in the primary outcome.
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Network meta-analysis of the mortality aggregate data from all 10 trials suggested that CPAP is the most
effective treatment (probability= 0.989), with an odds ratio (OR) for mortality of 0.41 [95% credible
interval (CrI) 0.20 to 0.77] compared with standard care. There was considerable uncertainty associated
with the effect of BiPAP relative to standard care (OR 1.94, 95% CrI 0.65 to 6.14). Sensitivity analysis,
excluding two quasi-randomised trials and one trial comparing early pre-hospital CPAP with late
pre-hospital CPAP, produced similar results, with CPAP being more effective than standard care (OR 0.45,
95% CrI 0.21 to 0.93), whereas the effect of BiPAP relative to standard care remained uncertain (OR 1.95,
95% CrI 0.43 to 9.46).
Network meta-analysis of the intubation aggregate data from 8 of the 10 trials (five CPAP trials and three
BiPAP trials) suggested that CPAP was the most effective treatment (probability= 0.639), with an OR for
intubation of 0.32 (95% CrI 0.17 to 0.62) compared with standard care. There was uncertainty associated
with the effect of BiPAP relative to standard care (OR 0.40, 95% CrI 0.14 to 1.16). Sensitivity analysis,
excluding one quasi-randomised trial and one trial comparing early pre-hospital CPAP with late
pre-hospital CPAP, produced similar results, with CPAP being more effective than standard care (OR 0.34,
95% CrI 0.15 to 0.77), whereas the effect of BiPAP relative to standard care remained uncertain (OR 0.53,
95% CrI 0.11 to 2.28).
Combining the IPD and aggregate data in the NMA suggested that sex was a statistically significant
treatment effect modifier of mortality at a conventional 5% significance level. There was evidence that
gender modifies the effect of CPAP relative to usual care [males : females OR 0.18, 95% CrI (0.04 to
0.74)] but no evidence that gender modifies the effect of BIPAP relative to usual care. The NMA of the
combined IPD and aggregate data on intubation suggested that none of the covariates was a treatment
effect modifier at a conventional 5% significance level.
The economic analysis showed that pre-hospital CPAP was more effective than standard care but was also
more expensive, with an ICER of £20,514 per QALY and a 49.5% probability of being cost-effective at
the £20,000 per QALY threshold. Scenario analysis showed that, compared with the general population
scenario, pre-hospital CPAP was more likely to be cost-effective in a rural population scenario (ICER
£18,744 per QALY, 58.8% probability of being cost-effective at the £20,000-per-QALY threshold) and less
likely to be cost-effective in an urban population scenario (ICER £21,284 per QALY, 41.5% probability).
Scenario analysis also showed that the incidence of patients likely to benefit from pre-hospital CPAP was
an important determinant of cost-effectiveness. A low estimate of incidence resulted in a high ICER
(£22,368 per QALY) and a low probability of being cost-effective (35.4% at the £20,000 per QALY
threshold), while a high estimate of incidence resulted in a lower ICER (£11,248 per QALY) and a high
probability of being cost-effective (93.8% at the £20,000-per-QALY threshold). If a typical ambulance
service treated 175 appropriate patients per year, it could save 10.81 lives while incurring £235,683
additional costs, whereas, if a typical ambulance service treated 2000 appropriate patients per year,
it could save 123.52 lives while incurring £582,300 additional costs.
Expected value of information analysis was also dependent on the estimated incidence of appropriate
patients. The population EVPI is £1.9M at a low incidence and £22.5M at a higher incidence. Expected
value of partial perfect information (EVPPI) analysis suggested that the ‘effect of pre-hospital CPAP on
mortality’, ‘total costs of pre-hospital CPAP’ and ‘baseline mortality’ are the key parameters, with EVPPI
values of £156.12, £37.54 and £14.85 per patient, respectively. Population EVPPI for the three parameters
together at the threshold is estimated as £1.83M at a low incidence and £21.3M at a higher incidence of
appropriate patients. Similarly, the population EVSI for a RCT with 100 patients in each arm to estimate
baseline mortality and the effect of pre-hospital CPAP on mortality is estimated as £1.08M at low
incidence and £12.67M at a higher incidence. The cost of a trial would probably lie between these values,
so the value of further research depends on the incidence of appropriate patients.
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Discussion
Pre-hospital CPAP appears to reduce mortality and intubation rate in acute respiratory failure. The
effectiveness of pre-hospital BiPAP is uncertain, with estimates of the effect on mortality and intubation
including the possibility of either worthwhile benefit or considerable harm. These findings were robust to
sensitivity analysis in which three trials were excluded on the basis of potential risk of bias or having an
inappropriate control group.
The NMA using both IPD and aggregate data suggested that male sex was a significant treatment effect
modifier of mortality, with CPAP being more effective in males. The pathological basis of this finding
is not clear, so it should be interpreted with caution. We found no such association in the analysis of
intubation data.
The implementation of pre-hospital CPAP is likely to incur substantial costs and, even if the estimates of
effectiveness from our meta-analysis are confirmed, it is uncertain if implementation would represent a
worthwhile use of NHS resources. There was particular uncertainty in our estimate of the incidence of
patients likely to benefit from pre-hospital CPAP, and variation in this parameter had a marked effect on
the cost-effectiveness of pre-hospital CPAP and the expected value of further research. It would be
cost-effective to conduct a trial with 100 patients in each arm if the overall cost of the trial is less than
£1.08M and the incidence of appropriate patients is at the lowest end of our range of estimates, or if the
overall cost is less than £12.67M and the incidence is at the highest end of our range of estimates.
Our systematic review includes more studies than previous reviews despite being the first to limit analysis
to randomised data. It is therefore more comprehensive and carries a lower risk of bias. It is possible,
however, that we may have missed unregistered trials, while the inclusion of quasi-randomised trials may
have introduced some bias. The primary studies were relatively small so meta-analysis may lack statistical
power to detect potentially important differences in mortality and intubation rates, particularly for the
comparison between pre-hospital BiPAP and standard care. Intervention was not always compared with
best alternative care. Patients eligible for pre-hospital NIV would be expected to receive in-hospital NIV if
pre-hospital treatment was not available, but this was clearly mandated in only one trial.
Additionally, the findings may not be generalisable to the NHS. The trials were small and may have
recruited highly selected patient groups. None of the trials was undertaken in the UK and the methods
used to deliver pre-hospital NIV (physician or paramedics with online physician support) would not be usual
NHS practice.
The validity of the economic analysis depended on the validity of the effectiveness analysis. If the effect of
pre-hospital CPAP on mortality has been overestimated, then the cost-effectiveness of pre-hospital CPAP
has also been overestimated.
Conclusions
Pre-hospital CPAP can reduce mortality and intubation rates for patients with acute respiratory failure, but
the available evidence has some limitations and may not be generalisable to the NHS. Furthermore, the
costs of establishing and running pre-hospital CPAP are substantial, and cost-effectiveness is uncertain.
Further evidence of feasibility, clinical effectiveness and cost-effectiveness in the NHS setting is therefore
required before implementation of pre-hospital CPAP can be recommended. The available evidence does
not support the use of pre-hospital BiPAP, and providing pre-hospital NIV by this method is unlikely to be
appropriate in the NHS.
SCIENTIFIC SUMMARY
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A feasibility study of pre-hospital CPAP in one ambulance service could address important uncertainties
without incurring prohibitive risks or costs. It could determine the incidence of patients transported
by emergency ambulance who are eligible for pre-hospital CPAP (an important determinant of
cost-effectiveness and the feasibility of any trial) and if pre-hospital CPAP can be appropriately used in the
NHS, and explore if barriers to pre-hospital recruitment and randomisation can be overcome. If feasibility is
demonstrated, a large pragmatic trial could compare pre-hospital CPAP with best alternative practice.
Study registration
The study is registered as PROSPERO CRD42012002933.
Funding
The National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Description of the health problem
Respiratory failure occurs when disease of the heart or lungs leads to failure to maintain adequate blood
oxygen levels (hypoxia) or increased blood carbon dioxide levels (hypercapnia). By definition, hypoxaemic
respiratory failure is characterised by an arterial oxygen tension (PaO2) of < 8 kPa (60mmHg) with normal or
low arterial carbon dioxide tension (PaCO2).1 In contrast, hypercapnic respiratory failure is the presence of
a PaCO2 > 6 kPa (45mmHg) and PaO2 < 8 kPa. Respiratory failure can be acute (develops within minutes
or hours in patients with no or minor evidence of pre-existing respiratory disease), acute on chronic (an acute
deterioration in an individual with pre-existing respiratory failure) or chronic (develops over several days or
longer in patients with existing respiratory disease).1
Acute respiratory failure is a common but life-threatening medical emergency, especially in elderly patients
(aged ≥ 65 years) with respiratory and cardiac diseases.2–4 As patients with acute respiratory failure
constitute a highly heterogeneous group, epidemiological data are sparse. Nevertheless, pneumonia,
chronic obstructive pulmonary disease (COPD), acute lower respiratory infection and heart failure are the
main causes of acute respiratory failure and were together responsible for 379,731 hospital admissions in
England in 2009–10. Some 53,608 (14%) of these patients died within 30 days of admission,5 typically
after developing acute respiratory failure. With an ageing population, coupled with improved survival
following an episode of acute respiratory failure, the burden of acute respiratory failure on the NHS is likely
to continue to increase.
The definitive treatment of acute respiratory failure depends on the underlying cause, but patients often
require treatment in the ambulance while en route to hospital (pre-hospital treatment). At this point it is
difficult to accurately determine the underlying cause, so pre-hospital treatment of acute respiratory failure
often follows a common pathway rather than being specific to the underlying cause. Around 10% of
medical admissions to hospital via emergency ambulance arrive at hospital with hypoxia (peripheral oxygen
saturation below 92%) despite pre-hospital oxygen therapy [Goodacre S. Unpublished data from the
DAVROS study (Development And Validation of Risk-adjusted Outcomes for Systems of Emergency Care)
2006–2011. 2013]. The risk of death in patients with respiratory problems increases markedly with
distance travelled to hospital, from 10% at distances below 10 km to 20% at distances over 20 km.6
This may be because many hospital treatments for acute hypoxaemic respiratory failure, particularly those
involving respiratory support, are not routinely available in the pre-hospital setting.
Acute non-invasive ventilation (NIV) involves providing respiratory support through a tight-fitting mask,
which is usually applied around the patient’s mouth and nose. It may take the form of continuous positive
airway pressure (CPAP) or bilevel inspiratory positive airway pressure (BiPAP). Acute NIV is usually used in
hospital but can be administered en route to hospital. CPAP is simpler to use and thus more suitable for
pre-hospital care. Acute respiratory failure is often associated with elevated carbon dioxide levels and
acidosis, in addition to hypoxia. In patients with chronic respiratory disease, oxygen therapy may reduce
respiratory drive and worsen hypercapnia and thus outcome. BiPAP can improve gas exchange and
outcome in these circumstances.
Current service provision
Pre-hospital care is provided by ambulance services in the UK in accordance with clinical practice guidelines
from the Joint Royal Colleges Ambulance Liaison Committee (JRCALC).7 Treatment pathways for the
management of acute respiratory failure follow a standardised and structured approach to initial
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assessment often referred to as the ABCDE (airway, breathing, circulation, disability, exposure) approach.
This allows the treating clinician to rapidly assess and treat any immediately life-threatening problems
before progressing to a more detailed assessment of the underlying cause of respiratory failure. The
JRCALC guidelines7 provide general guidance for the treatment of patients with dyspnoea and specific
guidance for the treatment of asthma and COPD. General management options include patient
positioning, assisted ventilation and supplemental oxygen. Specific management options for patients with
suspected asthma or COPD include nebulised salbutamol and ipratropium bromide, intramuscular
adrenaline and intravenous steroids.
On arrival at hospital a more detailed assessment can take place, involving a detailed clinical history and
examination, followed by investigations such as chest radiography and arterial blood gas analysis. This
allows the clinician to initiate treatments that are tailored to the underlying condition, while continuing
with general management measures. In-hospital NIV is widely used in the NHS to treat acute respiratory
failure that is refractory to initial medical therapy.1,8–15 Treatment is delivered predominantly in the
emergency department, acute medical/respiratory ward and critical care units. A common pathway of care,
based on NIV application in the hospital setting, is summarised in Figure 1.
If NIV is contraindicated or fails to reverse acute respiratory failure, then intubation may be required.
However, thresholds for intubation are not typically the same as those for providing NIV. Intubation
requires sedation and neuromuscular paralysis followed by admission to the intensive care unit. This is
likely to result in recovery with worthwhile quality of life only if the patient’s health and functional status
were reasonable before the acute illness. Patients presenting with acute respiratory failure who have severe
underlying disease and multiple comorbidities may benefit less from intubation and invasive ventilation.
NIV, however, does not require sedation or neuromuscular paralysis and can be appropriately used in
patients with relatively severe underlying disease.
The use of NIV is included in several national clinical practice guidelines for acute respiratory failure.
For patients presenting to hospital with an acute exacerbation of COPD, the National Institute for Health and
Care Excellence (NICE) guidelines16 recommend NIV as the treatment of choice for persistent hypercapnic
ventilatory failure during an acute exacerbation. It is recommended that treatment is restricted to those not
responding to standard medical therapy (controlled oxygen therapy, nebulisers and corticosteroids).
The European Society of Cardiology recommends that NIV may be considered for use in dyspnoeic patients
with pulmonary oedema and a respiratory rate > 20 breaths/minute to improve breathlessness and reduce
hypercapnia and acidosis.17 By contrast, the British Thoracic Society advises caution about the use of NIV in
patients presenting with respiratory failure secondary to pneumonia or asthma.1 If NIV is provided in these
situations it should be done so in the setting of a critical care unit, where rapid access to invasive
ventilation is immediately available in the event of treatment failure.
Although pre-hospital NIV is used in several European countries, it is not used routinely by UK NHS
ambulance services or recommended in JRCALC guidance. However, the recent UK Ambulance Services
Clinical Practice Guidelines 20137 recommended (for the first time) the use of CPAP in the pre-hospital
environment on the basis of expert consensus.
Conceptually, the use of pre-hospital NIV is attractive as it would allow treatment to be initiated earlier.
However, the pre-hospital setting differs from the in-hospital setting in a number of ways, which means
that the results from in-hospital trials18–25 cannot be directly translated. Specifically, the initial assessment
of patients is limited by the difficulty in conducting a full clinical examination and by the absence of
diagnostic investigations, which creates less certainty about the underlying diagnosis. During pre-hospital
treatment and transfer to hospital, the paramedic is isolated from the critical care support services that
are immediately available in an acute hospital in the event of deterioration. The equipment available is
likely to be limited by space constraints in the ambulance vehicle. These factors raise uncertainty about the
effectiveness of pre-hospital NIV in the UK NHS.
BACKGROUND
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Patient presents with acute
respiratory failure
ABCDE assessment
Immediate need for intubation
Obtain history
Examination
Investigations
Initiate supportive 
medical care
If no improvement, 
initiate NIV
Reassess at 1 hour
Intubate
CPAP
BiPAP
CPAP
Patient with ACPO Patient with COPD
Stabilised/
improving 
Continue Consider
intubation
Yes
No
Other
BiPAP
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FIGURE 1 Simplified in-hospital care pathway for management of patients with acute respiratory failure.
ABCDE, airway, breathing, circulation, disability, exposure; ACPO, acute cardiogenic pulmonary oedema.
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The potential delivery of pre-hospital NIV across the UK is associated with considerable variation and
uncertainty. This may partly be due to changing service configuration within the health-care setting as well
as available relevant medical personnel, expertise and NIV equipment. In addition, as clinical management
options can be adopted outside the UK Ambulance Clinical Practice Guidelines 20137 (depending on the
priorities of an ambulance service clinical group), this may lead to variations in uptake, training, equipment
and outcomes.
Description of the technology under assessment
Non-invasive ventilation is a form of positive-pressure respiratory support delivered to a spontaneously
breathing patient who does not require the use of an invasive and artificial airway, for example an
endotracheal tube or laryngeal mask.1 NIV differs from invasive techniques because it does not bypass the
upper respiratory tract.1 The potential advantages of NIV over conventional management in selected
patients include reduced breathlessness, improved arterial blood gases, and decreased intubation rates,
mortality, morbidity and in-hospital length of stay.20,23–25 Additionally, NIV is associated with less difficulty in
weaning from invasive mechanical ventilation.26 This is because NIV allows voluntary coughing, reduces the
need for sedation and muscle relaxants and supports self-feeding and communication.27,28 Commonly
reported complications of NIV include aspiration pneumonia, gastric distension, vomiting, pressure lesions
or sores, interface device leaks, intolerance to NIV and ventilator asynchrony.29
Non-invasive ventilation modes or modalities have been described in different ways.30 The ventilatory mode
may be defined according to the method of gas flow administration. Commonly used NIV modes include
CPAP and BiPAP ventilation.
The administration of CPAP involves the application of constant positive airway pressure during inspiration
and expiration using a pressure compressor or a flow generator.29,31 This mode is suitable for patients who
are breathing spontaneously because it can only provide support to an underlying respiratory drive.29,31,32
CPAP improves ventilation–perfusion matching and thereby improves oxygenation.29 Other physiological
effects of this mode of NIV include a reduction in venous return and a decrease in left ventricular wall
stress; both effects result in an improvement in cardiac output.29 This is particularly important in patients
with acute cardiogenic pulmonary oedema (ACPO). There is no recommended initial pressure setting
for CPAP; however, this may be determined by the patient’s age and the nature and severity of
underlying disease.29
Bilevel inspiratory positive airway pressure or non-invasive pressure-support ventilation involves the
application of preset inspiratory and expiratory pressures which may be time-triggered by preset controls
(controlled ventilation) or flow-triggered by the patient’s airway pressure (assisted ventilation).29 The
recommended initial inspiratory positive airway pressure (IPAP) is 10 cmH2O, and IPAP is increased in steps
of 2–5 cmH2O or at a rate of approximately 5 cmH2O every 10 minutes. It is advised that an expiratory
positive airway pressure (EPAP) of 4–5 cmH2O should be applied concurrently.15 A pressure support level
at 20 cmH2O is eventually maintained during BiPAP application.
For the available NIV modes, a variety of interface devices, for example helmets, full-face (facial) masks,
nasal masks, oronasal masks and mouthpieces, can be used to provide a connection for transport of
pressurised gas between the ventilator tubing and the patient’s upper airway.31 Despite this broad variety,
Schönhofer and Sortor-Leger33 found that the use of facial masks (≈ 70%) predominated, followed by
nasal masks (≈ 25%) and nasal pillows (≈ 5%), in the administration of NIV in patients with acute
respiratory failure. In the paediatric population, nasal pillows are commonly used.29
Extensive research has evaluated the in-hospital role of NIV for various causes of acute respiratory failure.
Meta-analysis of in-hospital trials for COPD21 has shown that NIV in conjunction with usual care,
compared with usual care alone, is associated with reduced mortality [n= 7 studies; relative risk 0.41,
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95% confidence interval (CI) 0.26 to 0.64] and need for intubation (n= 8 studies, relative risk 0.42,
95% CI 0.31 to 0.59). A systematic review of in-hospital trials of NIV for pneumonia found equivocal
effects, especially in patients without COPD.20 Several meta-analyses of NIV in ACPO have found reduced
mortality and intubation rates.19,22,23 The Three Interventions in Cardiogenic Pulmonary Oedema (3CPO)
trial, which was published after the meta-analyses, found that NIV improved physiological parameters and
symptoms of breathlessness in ACPO but did not reduce mortality or intubation rates.18
It has been argued that NIV is more likely to be effective if used early in the course of respiratory failure,
before fatigue develops.34 This raises the possibility that pre-hospital NIV could be more effective than
in-hospital NIV. Less research has been undertaken evaluating the pre-hospital use of NIV, but a number of
recent reviews have indicated that pre-hospital NIV is feasible and beneficial in selected patients with acute
respiratory failure.35,36
A number of issues need to be considered in relation to the provision of pre-hospital NIV. The equipment
needs to be suitable for pre-hospital use. Features of NIV devices for use in the pre-hospital setting include
a compact size, portability, robust construction, ability to work with oxygen only rather than requiring
compressed air, as well as compatibility with a range of available power sources.32 Few, if any, of the
existing BiPAP technologies meet these stringent requirements. As a result of these factors, and the
available technologies, it is considered that, in pre-hospital care in the UK, it is currently more feasible to
deliver CPAP than other forms of NIV.
Pre-hospital NIV is generally administered by paramedics or emergency medical teams, which may include
a physician, nurse or respiratory technician or therapist. To our knowledge, pre-hospital use of NIV is
currently limited in the UK to critical care paramedics in a few specific settings, such as the South East
Coast Ambulance Service. However, interest in providing NIV is growing. In the USA, the National
Association of Emergency Medical Service Physicians stated that NIV is an important treatment modality for
the pre-hospital management of acute dyspnoea.37 In the UK, it was identified among research priorities by
a recent 999 emergency medical services research forum.38
With around 16,000 paramedics and 5500 ambulance vehicles in England, widespread adoption of NIV
into paramedic practice would require substantial resources of training and equipment. Widespread
provision of pre-hospital NIV will require substantial resources, training and reorganisation. It is currently
not clear if existing evidence justifies widespread use of pre-hospital NIV. It is also not clear what further
evidence would be required to reduce uncertainty and help decision-making.
Pre-hospital treatment of acute respiratory failure also has substantial knock-on costs for the health service.
Patients with life-threatening respiratory illness often require prolonged hospital stay and/or critical care
involvement owing to the requirement for ventilatory support. Inadequate or inappropriate initial
management can result in the need for respiratory support and critical care admission. Conversely, the
appropriate use of early intervention can reduce the need for intubation and ventilation, thus reducing
critical care costs.
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Chapter 2 Research questions
Rationale for the study
Pre-hospital NIV has the potential to reduce mortality from acute respiratory failure, but widespread
provision of pre-hospital NIV will require substantial resources, training and reorganisation. It is currently
not clear if existing evidence justifies widespread use of pre-hospital NIV. In-hospital studies of NIV suggest
benefit in some conditions and uncertainty in others. Arguments can be made for pre-hospital NIV being
either more effective or less effective than in-hospital NIV, so findings from in-hospital studies cannot be
automatically extrapolated to the pre-hospital setting. A number of trials of pre-hospital NIV have been
undertaken but they have not been subject to comprehensive systematic reviews and their findings have
not been synthesised using the best current methods. A systematic review and meta-analysis is therefore
required to determine whether or not the currently available evidence supports pre-hospital use of NIV.
Even if there was reliable evidence of effectiveness, this would not necessarily justify widespread
implementation of pre-hospital NIV. The costs of such implementation could be substantial and could
represent poor value for health-care resources if pre-hospital NIV were applied to a small number of
patients only or associated with a small health benefit. An economic analysis is therefore required to
determine the cost-effectiveness of pre-hospital NIV compared with standard usual care for acute
respiratory failure. Issues of practicality, available equipment and training mean that pre-hospital CPAP
is the most likely form of pre-hospital NIV to be widely implemented in the NHS, so economic analysis
needs to focus on pre-hospital CPAP rather than BiPAP.
Finally, it is not clear what further evidence would be required to reduce uncertainty and help
decision-making. Undertaking a large randomised trial of pre-hospital NIV would reduce uncertainty,
but it is not clear whether or not the current evidence base justifies such a substantial undertaking.
Expected value of information analysis is therefore required to determine whether or not further research
into pre-hospital NIV would represent a cost-effective use of health-care resources and identify where
future research would be best focused.
Overall aims and objectives of assessment
The overall aim was to determine the clinical effectiveness and cost-effectiveness of pre-hospital NIV for
acute respiratory failure and identify priorities for future research. More specifically the objectives were:
1. to undertake a systematic review [including individual patient-level data (IPD) meta-analysis, if
appropriate data were available] to determine the effectiveness of pre-hospital NIV in patients with
acute respiratory failure
2. to develop an economic model to (a) estimate the incremental cost per quality-adjusted life-year (QALY)
gained by providing pre-hospital NIV (specifically pre-hospital CPAP) instead of standard care;
(b) estimate the additional costs incurred by establishing and providing pre-hospital CPAP, and the lives
saved and QALYs gained across the population served by a typical ambulance service; and (c) estimate
the expected value of information associated with reducing uncertainty around key parameters.
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Chapter 3 Assessment of clinical effectiveness
We carried out a systematic review of the literature and a network meta-analysis (NMA) to evaluate theclinical effectiveness of pre-hospital NIV in patients with acute respiratory failure.
The review of the evidence was carried out in accordance with the general principles recommended in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.39
Methods for reviewing effectiveness
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases and research registers:
l MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE (via OvidSP) from 1948 to
August 2013
l EMBASE (via OvidSP) from 1980 to August 2013
l Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) from 1982 to August 2013
l Cochrane Database of Systematic Reviews (via Wiley Online) from 1996 to August 2013
l Cochrane Central Register of Controlled Trials (via Wiley Online) from 1898 to August 2013
l Health Technology Assessment Database (via Wiley Online) from 1995 to August 2013
l Database of Abstracts of Review of Effects (via Wiley Online) from 1995 to August 2013
l Bioscience Information Service (BIOSIS) Previews (via ISI Web of Knowledge) from 1969 to August 2013
l Science Citation Index Expanded (via Web of Science) from 1899 to August 2013
l Conference Proceedings Citation Index – Science (via Web of Science) from 1990 to August 2013
l UK Clinical Research Network Portfolio Database [National Institute for Health Research (NIHR)] from
2001 to October 2012
l National Research Register Archive (NIHR) from 2000 to September 2007
l Current Controlled Trials from 2000 to October 2012
l ClinicalTrials.gov (USA National Institutes of Health) from 2000 to October 2012.
Sensitive keyword strategies were developed using free text and, where available, thesaurus terms using
Boolean operators and database-specific syntax to search the electronic databases. Synonyms relating to
the setting (e.g. pre-hospital) were combined with terms for NIV. No language or date restrictions were
used on any database. All resources were initially searched from inception to October 2012. With the
exception of the four research registers, updated searches to August 2013 were conducted on the
remaining electronic databases. An example of the MEDLINE search strategy is provided in Appendix 1.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies
were checked and a citation search of relevant articles (using the Web of Science, Science Citation Index
Expanded and Conference Proceedings Citation Index – Science) was undertaken to identify articles
that cite the relevant articles. In addition, systematic keyword searches of the internet were undertaken
using the Google search engine (Google Inc., Mountain View, CA, USA) and key experts in the field
were contacted.
All identified citations from the electronic searches and other resources were imported into and managed
using the Reference Manager bibliographic software version 12.0 (Thomson Reuters, Philadelphia, PA, USA).
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Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were
examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion criteria
(e.g. non-human, unrelated to acute respiratory failure) were excluded. Second, all abstracts and full-text
articles were examined independently by two reviewers. Any disagreements in the selection process were
resolved through discussion. The relevance of each article for the systematic review was assessed in
accordance with the criteria below.
Study design
All randomised (individual or cluster) or quasi-randomised controlled trials that evaluated pre-hospital NIV
(as part of acute treatment by the emergency care system) in patients with acute respiratory failure were
included. Non-randomised observational studies were not included in the formal systematic review but
were retained and reported descriptively as additional evidence and, if appropriate, used to develop the
economic model. In addition, all trials in progress (identified via trial registers) were recorded but not
included in the analysis.
The following publication types were excluded from the review: animal models; pre-clinical and biological
studies; narrative reviews, editorials, opinions; non-English-language papers; and reports published as
meeting abstracts only, where insufficient methodological details are reported to allow critical appraisal of
study quality.
Population
All studies of adults (defined as > 18 years of age) presenting to the emergency services with acute
(hypoxaemic or hypercapnic) respiratory failure from any cause or no specified cause were included.
Interventions
Pre-hospital NIV (defined as ventilatory support provided before arrival at hospital and delivered to a
spontaneously breathing individual without airway intervention) requiring BiPAP or CPAP interventions
were included. Head-to-head studies that compared different applications of NIV (e.g. CPAP vs. BiPAP)
or different interfaces (e.g. NIV with a face mask vs. NIV with a helmet) were excluded.
Relevant comparators
The relevant comparator was considered to be usual care. This consisted of any alternative treatment to
pre-hospital NIV, including standard oxygen therapy, standard medical therapy, delayed NIV or
in-hospital NIV.
Outcomes
The outcomes of the review included the need for intubation, mortality (within 30 days), measures of
breathlessness or respiratory function and patient-relevant outcomes.
Data abstraction strategy
Data abstraction was performed by one reviewer into a standardised data extraction form and independently
checked for accuracy by a second reviewer. Discrepancies were resolved by discussion between the two
reviewers and, if agreement could not be reached, a third reviewer was consulted. Where multiple
publications of the same study were identified, data were extracted and reported as a single study.
The following information was extracted for all studies when reported: study characteristics (e.g. author,
year of publication, country, study design, setting, duration of follow-up, funding), participant details
(e.g. age, sex, diagnosis, comorbidities, baseline physiology), intervention [e.g. system used, pressure(s)
used, duration of treatment, practitioners providing intervention] and comparator (e.g. any use of NIV,
supplemental oxygen) details, including information on any specified co-treatments, and outcomes
(including definitions). Where applicable, the authors of all included randomised trials were contacted to
clarify details, obtain missing data and request IPD for meta-analysis.
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Quality assessment strategy
The methodological quality of each included study was assessed by one reviewer and independently
checked by another. Disagreements were resolved by discussion between the two reviewers and if
agreement could not be reached, a third reviewer was consulted. The study quality characteristics were
assessed according to (adapted) criteria based on those proposed by Verhagen et al.40 for randomised
controlled trials (RCTs). Further details are provided in Appendix 2.
Methods of data synthesis
The extracted data and quality assessment variables were presented for each study, both in structured
tables and as a narrative description. For each outcome of interest (mortality and the need for intubation),
a NMA was performed in two separate analyses using (1) aggregate data from all studies and (2) IPD from
authors who provided relevant data and aggregate data for studies where IPD were not available. A NMA
allows a comprehensive comparison of all interventions that are linked with respect to at least one
common intervention without breaking the randomisation within studies. The summary statistics that were
analysed were the numbers of patients who had an event. Potential treatment effect modifiers (age, sex,
provider, primary diagnosis, severity of acute respiratory failure and pre-hospital time delay) were explored
using a NMA combining both IPD and aggregate data. Where possible, univariate regression analyses of
the IPD from individual studies were performed to identify potential treatment effect modifiers and
the plausibility of conducting a full NMA. A one-stage NMA of the most likely treatment effect modifiers
was then performed separately for each covariate. Any missing covariates in the IPD were assumed to
be missing completely at random and were imputed using multiple imputation by giving them a
prior distribution.
All models were analysed using Markov chain Monte Carlo techniques using a random-effects model
(to allow for heterogeneity in treatment effects across studies) implemented using the WinBUGS Version 1.4.3
(MRC Biostatistics Unit, Cambridge, UK)41,42 and OpenBUGS43 Version 3.2.3 (www.openbugs.net/w/FrontPage)
software package. Further details of the aggregate and combined IPD and aggregate data models are
presented in Appendices 3 and 4.
Convergence of the model to its posterior distribution was assessed using the Gelman–Rubin convergence
statistic (as modified by Brooks and Gelman).44 In each aggregate data NMA, convergence occurred within
10,000 iterations, so the final analysis used a burn-in of 10,000. In each combined IPD and aggregate data
NMA, convergence occurred within 50,000 iterations so the final analysis used a burn-in of 50,000. There
was some suggestion of moderate autocorrelation between successive iterations of the Markov chains;
to compensate for this, the Markov chains were thinned every five iterations. Parameter estimates were
estimated based on 10,000 iterations of the Markov chains. The total residual deviance was used to
formally assess whether or not the statistical model provided a reasonable representation of the sample
data. The total residual deviance is the mean of the deviance under the current model minus the deviance
for the saturated model, so that each data point should contribute about 1 to the deviance.
When competing models were used in the analysis, then the deviance information criterion (DIC)45 was
used to assess the goodness of fit. The DIC compares models based on a trade-off between the fit of the
data and the complexity of the fitted model, where the complexity of the model is measured by estimating
the effective number of model parameters. Lower DIC values indicate a better model choice.
Results of the NMA were reported in terms of odds ratios (ORs) and 95% credible intervals (CrIs) relative
to the baseline intervention (i.e. usual care). The 95% CrIs represent the 95% probability that the true
underlying effect lies in the interval specified. The posterior median of the between-study standard
deviation together with the 95% CrIs was also presented. To account for potential heterogeneity in
intervention effects between studies, the posterior predictive distribution for the OR from a hypothetical
new study was also presented.
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Results
Quantity and quality of research available
Number of studies identified/included
The literature searches identified 2284 citations. Of these, eight RCTs46–53 and two quasi-randomised
trials54,55 met the inclusion criteria. A flow chart describing the process of identifying relevant literature
can be found in Figure 2.
Number and type of studies excluded
A total of 55 full-text articles were excluded, as they did not meet all the prespecified inclusion criteria.
The majority of the articles were excluded primarily on the basis of inappropriate study design (non-RCT),
inappropriate setting (in-hospital NIV) or unsuitable publication type (reviews, commentaries or editorials).
One of the excluded studies (the VeNIS BPCO trial),56 which was identified on a trials register, was a planned
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FIGURE 2 Study flow chart (adapted): clinical effectiveness review.39
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open-label RCT that was designed to evaluate the effectiveness of pre-hospital NIV compared with standard
medical treatment in reducing intubation rates during acute respiratory failure in people with COPD. With
an estimated enrolment of 398 adult patients from France, the study was due for completion (final data
collection) in December 2014. However, at the time of writing, the study was not yet open for participant
recruitment. A full list of excluded studies with reasons for exclusion is presented in Appendix 5.
Assessment of effectiveness
Description of included studies (design and patient characteristics)
The design and patient characteristics of the 10 included studies46–55 that evaluated the effectiveness
of pre-hospital NIV for adults with acute respiratory failure are summarised in Tables 1–3.
All studies were published between 2000 and 2012. Studies were undertaken in a variety of countries and
settings including Australia,46 Europe (France,47,48,50 Germany51,52,55 and Spain49) and North America (Canada
53 and the USA54). The duration of follow-up was not reported in two studies;46,54 however, the length of
follow-up in the remaining studies ranged from 30 days48,51 to hospital discharge or death.47,49,50,52,53,55
Of the 10 studies, only one study55 recieved funding from one or more commercial sponsors. The design of
the included studies required the continuation of management of respiratory failure in the hospital setting
and in-hospital management was generally at the discretion of the treating physicians.
As all studies included patients with acute respiratory failure without immediate need for intubation
(i.e. spontaneously breathing patients), there was wide variation in terms of underlying conditions
resulting in respiratory failure. Six studies46–48,50,54,55 included a selected population of patients with ACPO. Of
these, two studies47,50 documented the exclusion of patients with COPD. Conversely, one study52 included
patients with acute respiratory failure due to COPD. One study53 enrolled a diverse population, including
patients with chronic heart failure, COPD, asthma, pneumonia and acute coronary syndrome with
respiratory failure. The sample sizes of the included studies ranged from 23 patients55 to 207 patients,47 with
the mean age of participants ranging from 68 years53 to 80 years.46,47 The percentage of male participants
ranged from 41%47 to 56%.46
Continuous positive airway pressure was the most commonly used mode of NIV in the intervention arm of
the included studies. While one study, that of Plaisance et al.,50 compared the effectiveness of early CPAP
(where patients had CPAP for the first 15 minutes after study inclusion, followed by CPAP with medical
treatment for 15 minutes) with late CPAP (where patients received conventional medical treatment with
supplementary oxygen for the first 15 minutes of study inclusion, followed by the addition of CPAP
for another 15 minutes), five studies46–48,52,53 provided CPAP to patients in the intervention group while
patients in the control group received conventional medical treatment only. Of the four studies49,51,54,55 that
assessed the use of BiPAP versus standard usual care, two were quasi-randomised trials.54,55 In the study by
Roessler et al.,51 NIV was initially started with CPAP; however, this was quickly changed to BiPAP, if CPAP
was tolerated (22 of 24 patients in the intervention group).
The NIV intervention in the included studies, where reported, was provided either by paramedics49,53,54 or
by an emergency physician.47,48,50–52,55 However, in the study by Thompson et al.53 the response to
out-of-hospital emergency calls was the responsibility of an advanced life support team of paramedics,
with ongoing online support provided by a physician, remotely. One study46 had no information relating to
medical personnel administering pre-hospital NIV.
Although two studies46,49 did not provide details relating to the NIV interface or pressure support levels,
eight studies47,48,50–55 used a face mask as the interface of choice for the administration of NIV. In RCTs
evaluating CPAP, pressure levels were fixed at 7.5 cmH2O50 or 10 cmH2O.48
,53 Applied pressure levels used
in other studies47,52 were determined by a titration method based on patient’s response to treatment and
degree of comfort. In these studies, the pressure support levels ranged from 5 cmH2O to 30 cmH2052
and from 7.5 cmH2O to 10 cmH2O.47 One study provided no details on pressure levels.46 In studies
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TABLE 3 Summary of patient characteristics at baseline: studies evaluating BiPAP
Variable
Author, year
Craven et al., 200054a Mas et al., 200249 Roessler et al., 201251
Weitz et al.,
200755
Population Adults experiencing
CHF with presumed
ACPO (dyspnoea with
increased RR, HR,
sweating, peripheral
oedema)
Adults presenting with
ARF (RR > 28 breaths/
minute, SpO2< 92% or
SpO2< 90% at any RR)
Adults presenting with
ARF owing to presumed
COPD or pneumonia with
signs of hypoxaemia
(SpO2<90%) or ventilator
failure (SpO2<90% with
RR >20 breaths/minute at
rest)
Adults with
presumed ACPO
(severe dyspnoea;
SpO2< 90%)
Age, mean (years) NR (median, 75) 78 74 77
Males (%) 45 NR 53 52
Diagnosis (primary) NR Acute pulmonary
oedema, n= 28; COPD
exacerbation, n= 17;
mixed diagnosis, n= 5;
other, n= 6
ACPO, n= 25; asthma,
n=1; COPD exacerbation,
n=17; pneumonia, n=6
Pulmonary
oedema, n= 20;
mixed diagnosis,
n= 3
Co-treatments Diuretics, nitrates, other
(not specified)
NR Furosemide, urapidil,
reproterol, dexamethasone,
opioids
Furosemide,
nitroglycerin,
morphine
Baseline physiology (mean ± SD)
pH NR NR 7.29± 0.11 7.31± 0.14
RR (breaths/minute) NR 36.25± 7.31 30.63± 6.47 29.47± 8.07
HR (beats/minute) NR 108.70± 25.96 116.04± 31.22 110.70± 22.75
Systolic BP (mmHg) NR 133.68± 21.26 164.27± 40.41 173.48± 36.13
SpO2 (%) NR 78.71± 10.05 77.24± 14.82 82.52± 6.44
PaO2 (mmHg) NR NR 216.44± 73.53 72.91± 18.51
PaCO2 (mmHg) NR NR 52.71± 16.83 49.03± 16.11
ARF, acute respiratory failure; BP, blood pressure; CHF, chronic heart failure; HR, heart rate; NR, not reported;
RR, respiratory rate; SD, standard deviation; SpO2, oxygen saturation.
a Data from published paper.
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evaluating BiPAP, a pressure of 12 cmH2O was applied in the study by Weitz et al.55 [positive end-expiratory
pressure (PEEP), 5 cmH2O; fraction of inspired oxygen (FiO2), 0.6], with pressure support titration to achieve
a tidal volume of 7ml/kg body weight or more in treated patients. Similarly, Roessler et al.51 adjusted
pressure support levels from 5 cmH2O to 20 cmH2O, depending on comfort (PEEP, 5–15 cmH2O). In
contrast, BiPAP with a fixed airway pressure support (EPAP 7 cmH2O; IPAP 19 cmH2O) was administered in
a study by Mas et al.49 No information was available relating to pressure support levels in the study by
Craven et al.54 However, this was the only study that reported that NIV was applied following transfer of
the patient into an ambulance equipped with the ventilation system.
Descriptions of the treatment schemes in the control groups were varied and included terminology such as
‘usual treatment’,54 ‘standard therapy’,49 ‘usual care’,46–48,53 ‘standard oxygen therapy’,52 ‘standard medical
treatment’51,55 or delayed NIV.50 As all control groups received conventional medical treatment together with
supplementary oxygen for the management of acute respiratory failure or its underlying cause, treatment in
the control groups is considered as usual care (standard oxygen therapy) throughout this report. The use of NIV
in the control group varied between studies. In the study by Plaisance et al.,50 which compared early CPAP with
late CPAP, NIV use in the control group was regarded as mandatory. Two studies, those of Roessler et al.51 and
Thompson et al.,53 reported that patients in the control groups were managed with NIV following admission
(n= 4/25 and n= 4/35, respectively). NIV use in the control group of these studies was, therefore, regarded as
allowed. Although no patients used NIV, Frontin et al.48 reported that their study allowed the use of NIV in the
control group. On the other hand, patients in the study conducted by Ducros et al.47 presenting with
intubation criteria could not receive any type of NIV support. These patients were intubated in the first
instance. In this study NIV use in the control group was considered to be prohibited. For the remaining
studies,46,49,52,54,55 the use of NIV in the control group was unclear.
Reporting of dosing regimens and number of patients in study groups receiving co-treatments varied
across studies. However, the commonest interventions were diuretics46–48,51,53–55 and nitrates.46,47,53–55
Quality characteristics
The overall methodological quality of the 10 included studies is summarised in Figure 3 and Table 4.
Generally, six studies performed well,47–51,53 receiving a positive assessment on at least six out of
nine methodological quality items.
Of the eight RCTs,46–53 only six studies reported the method of randomisation.47–51,53 In seven studies,47–53
similar methods for concealing treatment allocation were used: a randomly generated sequence of
treatment allocation concealed in sealed envelopes. Two studies were considered to be quasi-randomised
trials.54,55 In Weitz et al.55 the study design was described by the authors as a prospective, randomised trial.
However, the method of randomisation in this study was based on date of birth. This method of
Random sequence generation
Allocation of treatment concealed
Outcome assessment blinded
Eligibility criteria specified (including confirmation of respiratory failure)
Baseline comparability achieved for important prognostic indicators
Adequate follow-up of patients (at least 80%)
Reasons for withdrawal stated
Intention-to-treat analysis
Study powered to detect differences in outcomes
Item fulfilled
Yes (low bias)
No (high bias)
Unclear bias
Proportion fulfilled (%)
0 20 40 60 80 100
FIGURE 3 Methodological quality graph: review authors’ judgements about each methodological quality item as
percentages across all included studies.
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assignment (systematic allocation) is not considered as strictly random.57 In Craven et al.54 the study was
described by the authors as a prospective, sequential, parallel controlled trial. However, no details were
provided on the method of randomisation. Moreover, in this study, 10 emergency service units were
divided into five matched pairs (based on similar patient demographics). Five units (one of each matched
pair) were then equipped with a BiPAP ventilation system and five without. A convenience sample of
adults presumed to have chronic heart failure was given BiPAP by the emergency team during transport
and was compared with a control group that received usual care.
The potential sources of bias most frequently identified in studies concerned lack of blinding of outcome
assessment and lack of adequate power to detect differences in the primary outcome. Lack of blinding may
influence intubation rate (although in a pragmatic trial this may be acceptable) but is unlikely to influence
mortality. Many of the studies had small sample sizes (< 100 patients)46,49,51–55 so it is likely they had inadequate
statistical power to detect between-group differences, even if they were present. All of the included studies
were conducted outside the UK, making generalisability of the findings to the UK setting uncertain.
Effects of interventions
Network meta-analysis using aggregate data
A NMA was undertaken to compare the effectiveness of pre-hospital NIV for adults with acute respiratory
failure in terms of mortality and intubation.58 Figure 4 presents the network of evidence. A total of
10 studies46–55 comparing BiPAP or CPAP against standard care provided information on at least one
of the outcomes being analysed, although two studies did not provided information on intubation.46,55
A summary of all the trials (data) included in the base-case NMA is presented in Appendix 6.
TABLE 4 Methodological quality summary: review authors’ judgements about each methodological quality item
for each included study
Author, year
Methodological assessment criteria
1 2 3 4 5 6 7 8 9
Austin and Wills, 201246 (abstract) U U U U U U N U U
Craven et al., 200054 N N N Y N Y Y N U
aDucros et al., 201147 Y Y U Y Y Y Y Y N
aFrontin 2011 et al., 201148 Y Y Y Y Y Y Y Y Y
aMas et al., 200249a (abstract) Y Y N Y Y Y Y Y N
aPlaisance et al., 200750 Y Y N Y Y Y Y Y Y
aRoessler et al., 201251 Y Y N Y Y Y Y Y N
Schmidbauer et al., 201152 U Y U Y Y Y Y U U
aThompson et al., 200853 Y Y Y Y Y Y Y Y Y
Weitz et al., 200755 N N N Y N Y Y Y N
N, no (high risk of bias); U, unclear (insufficient detail to assess quality item); Y, yes (low risk of bias).
a At least six of the nine methodological quality items were fulfilled.
1=Was the method used to assign participants to the treatment groups really random?
2=Was the allocation concealment to each group performed adequately?
3=Were the outcome assessors/data analysts blinded to the treatment allocations?
4=Were the eligibility criteria for study entry specified (including confirmation of acute respiratory failure)?
5=Was baseline comparability achieved for the most important prognostic indicators?
6=Was follow-up of patients adequate (at least 80%)?
7=Were the reasons for withdrawal stated?
8=Was an intention-to-treat analysis included?
9=Was the study powered to detect differences in outcomes?
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Craven et al.54 performed a cluster randomised trial. However, we had no information on the intracluster
correlation coefficient and we did not adjust the effective sample size of this study. Consequently, this
study may contribute more information to the analysis than is appropriate. A sensitivity analysis was
performed by excluding data from Plaisance et al.50 because the control group received delayed
pre-hospital CPAP rather than in-hospital CPAP, and by excluding data from Craven et al.54 and Weitz et al.55
because neither was genuinely randomised.
Mortality Data were available from 10 studies,46–55 including six comparing CPAP46–48,50,52,53 with usual
care and four49,51,54,55 comparing BiPAP with usual care. However, there were no deaths in the
Schmidbauer et al.52 study, so this study provides no information about treatment effect. A summary of the
results from the NMA is presented in Table 5.
The NMA model fitted the data reasonably well, with a residual deviance close to the total number of
(non-zero) data points included in the analysis. The total residual deviance was 18.82, which compared
favourably with the 18 non-zero data points being analysed. The between-study standard deviation was
estimated to be 0.29 (95% CrI 0.02 to 0.85). This suggests that there was mild heterogeneity between
studies in the intervention effects, although with some uncertainty about the true variability in intervention
effects between studies.
There was evidence to suggest that CPAP is the most effective of the three interventions (probability= 0.989).
The effect of CPAP relative to usual care was statistically significant at a conventional 5% level (OR 0.41,
95% CrI 0.20 to 0.77). The heterogeneity in the effect of CPAP between studies meant that the effect
relative to usual care in a randomly chosen study varies according to the characteristics of the study (OR 0.41,
BiPAP CPAP
Standard care
Mortality, n = 4 
Intubation, n = 3
Mortality, n = 6
Intubation, n = 5
FIGURE 4 Network diagram of different pre-hospital NIV interventions vs. standard oxygen therapy (usual care) for
acute respiratory failure.
TABLE 5 Mortality in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds of
death relative to usual care (standard oxygen therapy) (random effects)
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 1.94 0.65 to 6.14 1.93 0.50 to 7.98 0.008
CPAP 0.41 0.20 to 0.77 0.41 0.14 to 1.16 0.989
Usual carea
Reference Reference Reference Reference Reference 0.004
Between-study standard deviation 0.29 0.02 to 0.85 – – –
a Usual care is defined as standard oxygen therapy with conventional medical treatment.
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95% CrI 0.14 to 1.16). There was considerable uncertainty associated with the effect of BiPAP relative to usual
care (OR 1.94, 95% CrI 0.65 to 6.14). The heterogeneity in the effect of BiPAP between studies meant that
the effect relative to usual care in a randomly chosen study varies according to the characteristics of the study
(OR 1.93, 95% CrI 0.50 to 7.98).
A sensitivity analysis was performed excluding the studies by Plaisance et al.,50 Craven et al.54 and
Weitz et al.55 A summary of the results from the NMA is presented in Table 6. There was little impact on
the heterogeneity in intervention effects between studies. As before, the intervention that exhibited the
greatest effect was CPAP (OR 0.45, 95% CrI 0.21 to 0.93), although the heterogeneity in the effect of NIV
between studies means that the intervention effects in a randomly chosen study varies substantially
depending on the characteristics of the study (OR 0.46, 95% CrI 0.13 to 1.41). The effect of BiPAP relative
to standard care remained uncertain (OR 1.95, 95% CrI 0.43 to 9.46).
Intubation rates Data were available from eight studies,47–54 including five47,48,50,52,53 comparing CPAP with
usual care and three studies49,51,54 comparing BiPAP with usual care. The analysis assumes that the lack
of intubation data from the studies of Weitz et al.55 and Austin and Wills46 are not related to the effects of
the interventions in these studies. A summary of the results from the NMA is presented in Table 7.
TABLE 7 Intubation rates in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds
of intubation relative to usual care (standard oxygen therapy) (random effects)
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 0.40 0.14 to 1.16 0.40 0.12 to 1.39 0.361
CPAP 0.32 0.17 to 0.62 0.32 0.13 to 0.82 0.639
Usual carea
Reference Reference Reference Reference Reference 0.000
Between-study standard deviation 0.21 0.01 to 0.73 – – –
a Usual care is defined as standard oxygen therapy with conventional medical treatment.
TABLE 6 Mortality in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds of
death relative to usual care (standard oxygen therapy) (random effects) – sensitivity analysis excluding the studies
of Plaisance et al.,50 Craven et al.54 and Weitz et al.55
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 1.95 0.43 to 9.46 1.95 0.33 to 11.47 0.039
CPAP 0.45 0.21 to 0.93 0.46 0.13 to 1.41 0.949
Usual carea
Reference Reference Reference Reference Reference 0.012
Between-study standard deviation 0.32 0.02 to 0.92 – – –
a Usual care is defined as standard oxygen therapy with conventional medical treatment.
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The NMA model fitted the data well, with a residual deviance, 16.05, close to the total number of data
points, 16, included in the analysis. The between-study standard deviation was estimated to be 0.21
(95% CrI 0.01 to 0.73). This indicated that there was mild heterogeneity between studies in the intervention
effects, although with some uncertainty about the true variability in intervention effects between studies.
Both patients treated with BiPAP and those treated with CPAP were less likely to require intubation than
those receiving usual care, although there was evidence to suggest that CPAP was the more effective
intervention (probability= 0.639). The effect of CPAP relative to usual care was statistically significant at a
conventional 5% level (OR 0.32, 95% CrI 0.17 to 0.62). The heterogeneity in the effect of CPAP between
studies meant that the effect relative to usual care in a randomly chosen study varies according to the
characteristics of the study (OR 0.32; 95% CrI 0.13 to 0.82). There was considerable uncertainty associated
with the effect of BiPAP relative to usual care (OR 0.40, 95% CrI 0.14 to 1.16).
A sensitivity analysis was performed excluding the studies of Plaisance et al.,50 Craven et al.54 and Weitz
et al.55 A summary of the results from the NMA is presented in Table 8. There was a small increase in the
between-trial standard deviation, although this is likely to be a consequence of there being fewer studies
rather than a genuine increase in heterogeneity in intervention effects between studies. As before, the
intervention that exhibited the greatest effect was CPAP (OR 0.34, 95% CrI 0.15 to 0.77), although
the heterogeneity in the effect of NIV between studies means that the intervention effects in a randomly
chosen study varies depending on the characteristics of the study (OR 0.34, 95% CrI 0.11 to 1.09).
The effect of BiPAP relative to standard care remained uncertain (OR 0.53, 95% CrI 0.11 to 2.28).
Network meta-analysis using combined individual patient-level data and
aggregate data
A NMA using combined IPD and aggregate data was undertaken to compare the comparative efficacy of
pre-hospital NIV for adults with acute respiratory failure on mortality and intubation. Of the 10 included
studies,46–55 IPD were available from only seven studies reporting a total of 650 patients.47–51,53,55 Potential
treatment effect modifiers were explored in separate analyses for age, sex, provider, primary diagnosis,
severity of acute respiratory failure and pre-hospital time delay. Data on pre-hospital time delay were not
well defined or reported and were not used in the analysis.
Mortality Despite the availability of IPD and aggregate data, a few discrepancies were noted. In the study by
Ducros et al.47 the number of events (i.e. death) reported in the intervention arm of the IPD set (n = 9) was higher
than that reported for the aggregate data (n = 8). Similarly, in the study by Frontin et al.,48 the number of events
reported in the control arm of the IPD set (n = 8) was also higher than that reported for the aggregate data (n = 7).
TABLE 8 Intubation rates in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds
of intubation relative to usual care (standard oxygen therapy) (random effects) – sensitivity analysis excluding
the studies of Plaisance et al.,50 Craven et al.54 and Weitz et al.55
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 0.53 0.11 to 2.28 0.53 0.09 to 2.87 0.306
CPAP 0.34 0.15 to 0.77 0.34 0.11 to 1.09 0.692
Usual carea
Reference Reference Reference Reference Reference 0.002
Between-study standard deviation 0.27 0.02 to 0.86 – – –
a Usual care is defined as standard oxygen therapy with conventional medical treatment.
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The preliminary analysis of each study suggested that age, sex, primary diagnosis (ACPO, COPD) and
respiratory rate could be the potential treatment effect modifiers (provider was not analysed because it
was a study-level covariate). There was insufficient information on patients with a primary diagnosis of
asthma and pneumonia to allow a meaningful estimate of treatment by diagnosis interaction; analyses
were performed but results were extremely uncertain (result not provided). A summary of the results from
the combined IPD and aggregate data NMA with covariates is presented in Tables 9 and 10.
In general, the DIC for models with and without covariates were within 5 units, which is the range
normally taken to mean that the models provide a similar fit to the data. However, when age was included
as a covariate, the DIC increased from 470.54 to 481.80, suggesting that including age resulted in a
worse-fitting model.
Combining the IPD and aggregate data in the NMA suggested that gender modifies the effect of CPAP
relative to usual care [males : females OR 0.18, 95% CrI (0.04 to 0.74)] but there was no evidence that
gender modifies the effect of BIPAP relative to usual care. After allowing for sex in the model, the
effects of both CPAP and BiPAP relative to usual care for females were not statistically significant at a
conventional 5% level for mortality (CPAP: OR 0.88, 95% CrI 0.34 to 2.20; BiPAP: OR 2.92, 95% CrI 0.44
to 21.82). The benefit of CPAP relative to usual care for males, in terms of reduced mortality, was
statistically significant at a conventional 5% significance (OR 0.16, 95% CrI 0.05 to 0.44). However, the
reduction in male mortality for BiPAP relative to usual care was not statistically significant at a conventional
5% significance level (OR 0.55, 95% CrI 0.08 to 3.40).
Intubation The preliminary analysis of each study suggested that sex, respiratory rate, oxygen saturation
(SpO2), PaO2 and PaCO2 could be the potential treatment effect modifiers (provider was not analysed because
it was a study-level covariate). Four studies were included in the analysis of whether or not PaO2 and PaCO2
were treatment effect modifiers: those of Ducros et al. 2011,47 Frontin et al. 2011,48 Plaisance et al. 200750
TABLE 9 Mortality in pre-hospital NIV patients with acute respiratory failure with continuous treatment effect
modifiers: posterior results for the odds of death relative to usual care (standard oxygen therapy) (random effects)
Variable
Potential treatment effect modifiera
Age Respiratory rate
Data source
IPD Ducros et al.,47 Frontin et al.,48
Plaisance et al.,50 Roessler et al.,51
Thompson et al.,53 Mas et al.49
and Weitz et al.55
Ducros et al.,47 Frontin et al.,48
Plaisance et al.,50 Roessler et al.,51
Thompson et al.,53 Mas et al.49
and Weitz et al.55
Aggregate data Austin and Wills,46 and Craven et al.54 –
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 1.04 (0.92 to 1.18) 0.88 (0.70 to 1.04)
CPAP 1.02 (0.97 to 1.08) 0.95 (0.88 to 1.03)
Treatment effect at the average value of the treatment effect modifier, OR (95% CrI)
BiPAP 2.44 (0.76 to 8.71) 2.66 (0.59 to 15.19)
CPAP 0.40 (0.19 to 0.77) 0.62 (0.28 to 1.29)
Between-study standard deviation (95% CrI) 0.31 (0.02 to 0.87) 0.30 (0.01 to 0.89)
DIC (model with treatment effect
modifier vs. model without treatment
effect modifier)
481.80 vs. 470.54 455.99 vs. 451.62
a Each potential treatment effect modifier was analysed separately in the model.
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TABLE 10 Mortality in pre-hospital NIV patients with acute respiratory failure with binary treatment effect
modifiers: posterior results for the odds of death relative to usual care (standard oxygen therapy) (random effects)
Variable
Potential treatment effect modifiera
Sex ACPOb COPDb Provider
Data source
IPD Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Roessler et al.51
and Weitz et al.55
Roessler et al.51
and Mas et al.49
Roessler et al.,51
Thompson et al.53
and Mas et al.49
–
Aggregate data Thompson et al.,53
Austin and Wills46
and Craven et al.54
Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Thompson et al.,53
Austin and Wills46
and Craven et al.54
Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Austin and Wills46
and Craven et al.54
Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Roessler et al.,51
Thompson et al.,53
Mas et al.,49
Weitz et al.,55
Austin and Wills46
and Craven et al.54
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 0.19 (0.01 to 2.44) 1.45 (0.25 to 9.44) 0.19 (0.01 to 1.70) 0.57 (0.06 to 3.59)
CPAP 0.18 (0.04 to 0.74) 1.30 (0.25 to 7.13) 0.27 (0.03 to 1.92) 1.43 (0.32 to 6.36)
Treatment effect at the average value of the treatment effect modifier, OR (95% CrI)
BiPAP Males: 0.55
(0.08 to 3.40)
Patients with ACPO:
2.07 (0.59 to 8.11)
Patients with COPD:
0.50 (0.04 to 4.34)
Physicians: 1.29
(0.19 to 7.45)
Females: 2.92
(0.44 to 21.82)
Patients without
ACPO: 1.41
(0.28 to 7.65)
Patients without
COPD: 2.58
(0.82 to 9.51)
Paramedics: 2.31
(0.72 to 8.83)
CPAP Males: 0.16
(0.05 to 0.44)
Patients with ACPO:
0.42 (0.20 to 0.81)
Patients with COPD:
0.12 (0.01 to 0.83)
Physicians: 0.55
(0.24 to 1.19)
Females: 0.88
(0.34 to 2.20)
Patients without
ACPO: 0.32
(0.06 to 1.60)
Patients without
COPD: 0.45
(0.22 to 0.87)
Paramedics: 0.38
(0.10 to 1.41)
Between-study
standard deviation
(95% CrI)
0.32 (0.01 to 0.89) 0.31 (0.02 to 0.87) 0.30 (0.01 to 0.86) 0.25 (0.01 to 0.80)
DIC (model with
treatment effect
modifier vs. model
without treatment
effect modifier)
353.39 vs. 358.43 210.65 vs. 208.36 207.89 vs. 208.46 77.95 vs. 76.32
a Each potential treatment effect modifier was analysed separately in the model.
b Primary diagnosis.
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and Roessler et al. 2012.51 Three out of these four studies (Ducros et al. 201147, Frontin et al. 201148 and
Plaisance et al. 200750) compared CPAP with usual care, and only one study (Roessler et al. 201251) compared
BiPAP with usual care. Hence there were not enough studies to estimate the coefficient of the treatment
effect modifier for BiPAP, and whether or not PaO2 and PaCO2 were treatment modifiers was assessed only
for CPAP. A summary of the results from the combined IPD and aggregate data NMA with covariates is
presented in Tables 11 and 12.
The DIC suggested that the models with covariate SpO2 and PaO2 were a poorer fit for the data than the
model without these covariates. There is little to choose between models with covariates sex, respiratory
rate and provider and the models without these covariates, as the DIC for models with and without these
covariates were within 5 units. None of the coefficients of treatment effect modifiers was statistically
significant at a conventional 5% significance level.
The model with covariate PaCO2 fitted the data better than the model without this covariate. However,
PaCO2 was not a statistically significant treatment effect modifier at a conventional 5% significance level
(coefficient for the CPAP arm: OR 1.03, 95% CrI 0.96 to 1.10).
Additional evidence
Supplementary evidence from 20 non-randomised observational studies (representing 21 articles)59–79 with
relevant outcome data (namely intubation rates and mortality) from patients with acute respiratory failure
following the application of NIV in the pre-hospital setting were identified and are reported here as
additional evidence (i.e. data presented as structured tables with a narrative description, but without a
formal quality assessment or analysis).
TABLE 11 Intubation rates in pre-hospital NIV patients with acute respiratory failure with continuous treatment
effect modifiers: posterior results for the odds of intubation relative to usual care (standard oxygen therapy)
(random effects)
Variable
Potential treatment effect modifiera
Respiratory rate SpO2 PaO2 PaCO2
Data source
IPD Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Roessler et al.51 and
Mas et al.49
Ducros et al.,47
Frontin et al.,48
Plaisance et al.,50
Roessler et al.51 and
Mas et al.49
Ducros et al.,47
Frontin et al.48 and
Plaisance et al.50
Ducros et al.,47
Frontin et al.48 and
Plaisance et al.50
Aggregate data Thompson et al.53 Thompson et al.53 – –
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 0.94 (0.77 to 1.12) 1.02 (0.92 to 1.14) – –
CPAP 0.99 (0.90 to 1.10) 1.02 (0.95 to 1.11) 1.0 (0.99 to 1.02) 1.03 (0.96 to 1.10)
Treatment effect at the average value of the treatment effect modifier, OR (95% CrI)
BiPAP 0.50 (0.10 to 2.33) 0.57 (0.08 to 3.28) – –
CPAP 0.35 (0.15 to 0.83) 0.34 (0.15 to 0.74) 0.38 (0.14 to 0.97) 0.32 (0.11 to 0.82)
Between-study standard
deviation (95% CrI)
0.29 (0.01 to 0.91) 0.26 (0.01 to 0.87) 0.24 (0.01 to 0.81) 0.24 (0.01 to 0.81)
DIC (model with
treatment effect modifier
vs. model without
treatment effect modifier)
320.76 vs. 318.67 325.83 vs. 318.67 241.17 vs. 234.69 228.30 vs. 234.69
a Each potential treatment effect modifier was analysed separately in the model.
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Non-randomised observational studies with a control group Eight studies60,64–67,72,74,77 described the
use of pre-hospital NIV in patients with acute respiratory failure. A summary of the studies is presented
in Table 13. Studies were published between 2005 and 2013, and were undertaken in France,65 Italy,72
the Netherlands77 and the USA.60,64,66,67,74 Three studies64,72,74 collected data prospectively, while the
remaining studies used a retrospective study design.60,65–67,77
While all studies included patients with acute respiratory distress there was wide variation in terms of
underlying conditions resulting in respiratory failure. Moreover, in two studies,60,66 patients with acute
decompensated heart failure and chronic heart failure were also eligible for inclusion. These conditions
may be difficult to distinguish objectively from ACPO in the pre-hospital setting. The sample sizes of the
studies ranged from 42 patients65 to 467 patients,64 with the mean age of participants ranging from
68.9 years65 to 77.7 years72 (no details of mean age were provided in three studies).60,66,77
With the exception of one study65 (which provided limited data), all studies used CPAP as the mode of NIV
in the intervention group. Although two studies64,66 did not provide details relating to the CPAP interface
or pressure support level, four studies used a face mask60,67,74,77 and one used a helmet72 as the interface of
choice for the administration of CPAP. NIV was administered by paramedics in four studies60,67,74,77 and by
an ambulance nurse in one study.72 Three studies64–66 provided no information on the category of medical
personnel that administered pre-hospital NIV. Patients in the control groups were generally managed with
conventional medical treatments (usual care) including oxygen for respiratory distress.
TABLE 12 Intubation rates in pre-hospital NIV patients with acute respiratory failure with binary treatment effect
modifiers: posterior results for the odds of intubation relative to usual care (standard oxygen therapy)
(random effects)
Variable
Potential treatment effect modifiera
Sex Provider
Data source
IPD Ducros et al.,47 Frontin et al.,48
Plaisance et al.50 and Roessler et al.51
–
Aggregate Thompson et al.53 and Craven et al.54 Ducros et al.,47 Frontin et al.,48
Plaisance et al.,50 Roessler et al.,51
Thompson et al.,53 Mas et al.,49
Weitz et al.,55 Austin and Wills46
and Craven et al.54
Coefficient of treatment effect modifier, OR (95% CrI)
BiPAP 3.42 (0.26 to 43.80) 0.46 (0.04 to 2.81)
CPAP 3.61 (0.78 to 19.11) 1.12 (0.26 to 4.59)
Treatment effect at the average value of the treatment effect modifier, OR (95% CrI)
BiPAP Males: 0.37 (0.06 to 1.98) Physicians: 0.23 (0.02 to 1.21)
Females: 0.11 (0.02 to 0.63) Paramedics: 0.51 (0.15 to 1.70)
CPAP Males: 0.55 (0.21 to 1.43) Physicians: 0.33 (0.15 to 0.70)
Females: 0.16 (0.04 to 0.49) Paramedics: 0.30 (0.09 to 1.00)
Between-study standard deviation (95% CrI) 0.21 (0.01 to 0.74) 0.23 (0.01 to 0.80)
DIC (model with treatment effect
modifier vs. model without treatment
effect modifier)
298.76 vs. 293.92 80.229 vs. 76.318
a Each potential treatment effect modifier was analysed separately in the model.
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Comparison with non-randomised controls suggested lower intubation rates67,72,74,77 and mortality60,66,72,74,77
in patients receiving CPAP in addition to standard treatment. However, these non-randomised comparisons
carry a high risk of bias and are unlikely to provide useful evidence of effectiveness when randomised
comparisons are available. We did not therefore undertake further analysis of these data or attempt
to draw any conclusions from them regarding effectiveness.
Data from non-randomised studies can provide some useful information about outcomes when interventions
are used outside the trial setting. Mortality rates in the intervention groups ranged from 0%67 to 13.8%66
(median 7%), while intubation rates ranged from 0%72 to 22.3%60 (median 6%). These are similar to the
mortality rates (range 0–21%, median 9%) and intubation rates (range 0–17%, median 8%) reported in
the intervention groups of the randomised trials, suggesting that outcome rates reported in trials appear to be
reproduced in more routine practice.
Non-randomised observational studies without a control group Twelve studies61–63,68–71,73,75,76,78,79
described the use of pre-hospital NIV in patients with acute respiratory failure. A summary of the studies is
presented in Table 14. Studies were published between 2000 and 2013, and were undertaken in Finland,75
France,61,63,78 Greece,71,73 Italy,69 the Netherlands,68 Portugal,70 and the USA.62,76,79 Two studies61,75 collected
data retrospectively, while the remaining studies used a prospective study design.62,63,68–71,73,76,78,79
While all studies included patients with acute respiratory distress, there was wide variation in terms of
underlying conditions resulting in respiratory failure. The sample sizes of the studies ranged between
19 patients76 to 340 patients,62 with the mean age of participants ranging from 67.7 years62 to 78.3 years69
(no details of mean age were provided in four studies).68,73,75,79, In one study,61 the mean age of patients
was reported separately by underlying condition (asthma, 48 years and COPD, 68 years)
With the exception of one study (which used BiPAP via a single-use full-face mask),63 all studies used CPAP
as the mode of NIV in the intervention group. Although four studies61,70,71,79 did not provide details relating
to the CPAP interface, six studies used a face mask62,68,73,75,76,78 and one used a helmet69 as the interface of
choice for the administration of CPAP. NIV was administered by paramedics in two studies,62,76 physicians
in four studies,71,73,75,78 an ambulance nurse in one study,68 a physician or nurse in one study,69 and an
emergency service team in one study.79 Three studies61,63,70 provided no information on the category of
medical personnel that administered pre-hospital NIV.
In non-randomised studies without a comparative group, intubation rates ranged from 0%79 to 36.8%.76
Similarly, mortality rates ranged from 1.3%71 to 34.4%.68 This wide variation in rates may be explained by
differences in study populations and study methodologies in the included studies. Overall, intubation
rates and mortality rates were generally higher in studies without a control group compared with studies
with a control group.
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Chapter 4 Assessment of cost-effectiveness
This chapter provides details on the methods and results of the health economic model constructed toevaluate the cost-effectiveness of pre-hospital NIV (specifically pre-hospital CPAP) for patients with
acute respiratory failure. We developed a decision-analytic model to compare the costs and QALYs accrued
by a theoretical population with acute respiratory failure attended by emergency ambulances providing
pre-hospital CPAP to management by ambulances without pre-hospital NIV (standard care is assumed as
hospital NIV).
Systematic review of existing cost-effectiveness evidence
The objective of this review was to identify and evaluate studies exploring the cost-effectiveness of
pre-hospital NIV for patients with acute respiratory failure because of any cause or no specified cause.
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases and research registers:
l MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (via OvidSP) from 1948 to
August 2013
l EMBASE (via OvidSP) from 1980 to August 2013
l Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) from 1982 to August 2013
l Cochrane Database of Systematic Reviews (via Wiley Online) from 1996 to August 2013
l Cochrane Central Register of Controlled Trials (via Wiley Online) from 1898 to August 2013
l Health Technology Assessment Database (via Wiley Online) from 1995 to August 2013
l Database of Abstracts of Review of Effects (via Wiley Online) from 1995 to August 2013
l NHS Economic Evaluation Database (via Wiley Online) from 1995 to August 2013
l BIOSIS Previews (via ISI Web of Knowledge) from 1969 to August 2013
l Science Citation Index Expanded (via Web of Science) from 1899 to August 2013
l Conference Proceedings Index – Science (via Web of Science) from 1990 to August 2013
l EconLit (via OvidSP) from 1961 to August 2013
l UK Clinical Research Network Portfolio Database (NIHR) from 2001 to October 2012
l National Research Register Archive (NIHR) from 2000 to September 2007
l Current Controlled Trials from 2000 to October 2012
l ClinicalTrials.gov (US National Institutes of Health) from 2000 to October 2012.
The keyword strategies developed in the review of clinical effectiveness (see Chapter 3, Methods for
reviewing effectiveness, Identification of studies) were used with a sensitive economic evaluation (where
applicable) or quality-of-life search filter aimed at restricting search results to economic and cost-related
studies (used in the searches of MEDLINE, Cumulative Index to Nursing and Allied Health Literature and
EMBASE). All resources were initially searched from inception to October 2012. With the exception of the
four research registers, updated searches to August 2013 were conducted on the remaining electronic
databases. An example of the MEDLINE search strategy is provided in Appendix 7.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies
(including existing systematic reviews) were checked and a citation search of relevant articles (using the
Web of Science Citation Index Expanded and Conference Proceedings Citation Index – Science) was carried
out to identify articles that cite the relevant articles. In addition, systematic keyword searches of the World
Wide Web were undertaken using the Google search engine and key experts in the field were contacted.
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All identified citations from the electronic searches and other resources were imported into and managed
using the Reference Manager bibliographic software (version 12.0).
Inclusion and exclusion criteria
Studies were selected for inclusion according to predetermined inclusion and exclusion criteria. Studies
were included if they reported an economic evaluation of pre-hospital NIV for patients with acute
respiratory failure and estimated the benefits in terms of life-years gained or QALYs.
Studies that performed economic evaluations alongside trials were excluded if they did not extrapolate the
outcomes beyond the trial duration, as these economic analyses are only valid for the trials under consideration.
Studies that were considered to be methodologically unsound, that were not reported in sufficient detail to
extract costs and outcome estimates (including abstracts) or did not report an estimate of cost-effectiveness
(e.g. costing studies) were also excluded. Papers not published in the English language were also excluded.
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were
examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion criteria
were excluded. Second, all abstracts and full-text articles were examined independently by two reviewers
and any disagreements in the selection process were resolved through discussion.
Results of the cost-effectiveness review
The electronic literature searches identified 214 potentially relevant publications. Of these, one study80 met
the inclusion criteria. A flow chart describing the process of identifying relevant literature can be found in
Figure 5. Further details of the included study including an assessment of its methodological quality are
provided below.
Quality assessment strategy
The methodological quality of each included study was assessed using a combination of key components
of the Drummond and Jefferson81 and Drummond et al.82 guidelines for economic evaluations, together
with the Eddy checklist for mathematical models used in technology assessments.83 The use of the checklist
ensured a consistent approach to assessing the quality of each economic evaluation.
Cost-effectiveness review summary
Hubble et al.80 assessed the cost-effectiveness of pre-hospital CPAP compared with no CPAP in managing
ACPO in a typical urban ambulance service. Using estimates from published reports on pre-hospital and
emergency department CPAP, a cost-effectiveness model of implementing CPAP in a typical urban
ambulance service was derived from the societal perspective as well as the perspective of the implementing
service. The model used a 1-year time horizon. The theoretical service would be expected to use CPAP
four times per 1000 patients and expected to save 0.75 additional lives per 1000 patients at a cost of
US$490 per life saved. CPAP is also expected to eliminate the need for approximately one in six intubations
and reduce hospitalisation costs by US$4075 per year for each application. The model was verified to be
robust across a wide range of input variable assumptions.
Comments
The analysis was performed for patients with ACPO and the main outcomes measured were the reduction in
hospitalisation costs and mortality. In order to evaluate the clinical effectiveness, a meta-analysis of six
clinical trials of in-hospital CPAP was carried out. One of the limitations of this study is the use of
data from studies of emergency departments owing to a lack of adequate numbers of pre-hospital studies.
Most of the costs were presented in a detailed and systematic way. Initial capital costs of CPAP equipment
purchasing were expensed over a projected useful lifespan of 5 years. Training costs of different staff groups
and other resource costs were extracted from the trial data. One-way sensitivity analysis was performed, but
the authors did not perform a probabilistic sensitivity analysis. The model did not estimate QALYs as the
measure of effectiveness and thus, the cost-effectiveness analysis results are not applicable to the current
decision problem. Furthermore, the model used only a 1-year time horizon, which does not take the full
lifetime costs and outcomes into account. Thus, the validity of findings from this study is still uncertain.
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Independent economic assessment methods
This section details the methods and assumptions of the de novo economic model constructed to evaluate
the cost-effectiveness of pre-hospital NIV (specifically pre-hospital CPAP) compared with standard care
for patients with acute respiratory failure.
Objectives
The objectives of the cost-effectiveness analysis were to:
1. estimate the cost-effectiveness of pre-hospital CPAP compared with standard care for patients with
acute respiratory failure, in terms of the costs and QALYs gained by each strategy
2. identify the strategy that is most likely to be cost-effective for patients with acute respiratory failure,
defined as the most cost-effective strategy at a willingness-to-pay threshold of £20,000–30,000
per QALY gained
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FIGURE 5 Study flow chart (adapted): cost-effectiveness review.39
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3. identify the expected cost of pre-hospital CPAP and whether or not future research would be valuable
by estimating the expected value of perfect information (EVPI)
4. identify the critical areas of uncertainty where future research would produce most benefit and
recommend specific primary research designs to address the uncertainty around using expected value
of sample information (EVSI) techniques.
The costs and benefits of pre-hospital continuous positive airway pressure
The treatment of acute respiratory failure depends on the underlying cause, but patients often require
treatment in the ambulance while en route to hospital (pre-hospital treatment). The risk of death in
patients with respiratory problems increases markedly with distance travelled to hospital, from 10% at
distances below 10 km to 20% at distances over 20 km.
The main benefits of pre-hospital CPAP relate to the reduction of mortality and intubation rates for these
patients. Reduced intubation rates translate into reduced requirement for intensive care and hence
reduced health-care costs. Reduced short-term mortality translates into long-term health benefits in terms
of QALYs accrued by additional survivors.
The direct costs of pre-hospital CPAP include the costs of delivering the CPAP in the ambulance and the
subsequent costs of providing treatment in the hospital. Most of the costs of pre-hospital CPAP are set-up
costs, with small additional costs per patient treated. In order to set up a service of pre-hospital CPAP,
there are a number of initial costs such as equipment costs, staff training costs and service reconfiguration
costs. This is a key determinant of cost-effectiveness as the unit cost of pre-hospital CPAP will involve
dividing the total costs of providing CPAP by the number of patients treated and receiving benefit (i.e. the
number of patients treated will determine cost-effectiveness).
The decision-analytic model structure
A de novo economic model was developed using R software (The R Foundation for Statistical Computing)84
to explore the costs and health outcomes associated with pre-hospital CPAP and standard care. The
economic perspective of the model is the NHS in England and Wales with the structure of the model
shown in Figure 6.
Patients
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respiratory
failure
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Treatment costs
(based on length
of stay and
location of
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Long term
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Life expectancy
Pre-hospital CPAP
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QALYs
Short term
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Long term
Life expectancy
Health-related
quality of life
FIGURE 6 Model structure.
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The different interventions (pre-hospital CPAP and standard care) were applied to a hypothetical cohort of
patients with acute respiratory failure, that is, all patients receive pre-hospital CPAP in the intervention
group and standard care in the comparator group. The model assigned to each patient a probability of
intubation or death depending on their characteristics and whether they received pre-hospital CPAP or
standard care. The patients who survived accrued lifetime QALYs and health-care costs according to their
life expectancy. Costs were also accrued through costs of the intervention (i.e. pre-hospital CPAP) and
hospital treatment costs which depended on whether or not the patient needed intubation. Details of each
of these processes are outlined below.
Model structure
A decision-analytic model was developed to estimate the costs and health outcomes associated with
pre-hospital CPAP and standard care in a hypothetical cohort of patients with acute respiratory failure.
Population
The population consisted of a hypothetical cohort of patients with acute respiratory failure of any cause or
no specified cause in a given ambulance service setting. Although this cohort can include patients with
ACPO/heart failure, COPD or pneumonia, for the purpose of modelling they are treated as a single group.
Using an incidence rate, the annual number of instances of patients with acute respiratory failure for a
given ambulance service can be estimated based on the population served.
Intervention
There are multiple alternative specifications of the pre-hospital NIV approaches reported in the studies
included within the systematic review; the interventions were classified and specified as reported in
Chapter 3. These include (a) early CPAP provided by medical responders, (b) CPAP provided by paramedics,
(c) CPAP provided by medical responders, (d) BiPAP provided by medical responders and (e) BiPAP provided
by emergency physicians.
The clinical expert group decided that CPAP provided by paramedics was the approach most likely to be
feasible in the UK, based on knowledge of currently available equipment, training requirements,
anticipated costs, existing guidelines and the practicality of use in NHS ambulances. These factors all
suggested that the model of pre-hospital NIV delivery most likely to be used in the NHS was CPAP
delivered by paramedics. The meta-analysis would generate an estimate of treatment effect for the model
by assuming a general effect for CPAP, regardless of whether it was provided by paramedics or physicians.
Comparator
Again, there are multiple alternative specifications of standard care reported in the studies included within
the systematic review, which include (a) standard care without any NIV, (b) standard care with in-hospital
NIV and (c) delayed pre-hospital NIV.
However, for the purposes of the economic model, in-hospital NIV is chosen as standard care. This
assumption was deemed sensible by the clinical expert group, as any patient who received pre-hospital
CPAP appropriately would have received in-hospital NIV if pre-hospital CPAP were not available.
Outcomes
The main outcomes in the model were QALYs, which are accrued by patients who survive their acute
event (i.e. survive to 30 days).
Model perspective
The model took a lifetime horizon and the economic perspective of the model was the NHS in England
and Wales.
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Discount rate
Both the costs and QALYs were discounted at an annual discount rate of 3.5%, as recommended by NICE.85
The key modelling methods together with the evidence sources and assumptions used to populate the
model are discussed in detail in the following sections, Short-term outcomes, Effect of pre-hospital
continuous positive airway pressure, Long-term health outcomes and Costs.
Short-term outcomes
Patients with acute respiratory failure are at increased risk of both fatal and non-fatal major adverse
cardiovascular events. The main outcomes of interest were short-term mortality and risk of intubation. The
model estimated the prognosis of each patient by using a 30-day probability of death and probabilities of
intubation depending on the type of treatment. This subsection details the baseline risks of intubation and
death (i.e. for patients in standard care) estimated using data from the literature and the effectiveness of
pre-hospital NIV in reducing mortality and intubation risks from NMA.
Mortality risk
The primary outcome measure, mortality, was typically recorded as a binary outcome and results presented as
the response rate at 30 days. This 30-day mortality includes deaths in the ambulance and in the hospital.
The mortality risk of emergency admissions with respiratory illness was modelled using a large cohort data
set of 668 patients presented with ‘respiratory disease’ across four ambulance services over a 4-year period
from 1997 to 2001.6 These were the Royal Berkshire Ambulance Service, the Derbyshire Ambulance Service,
the Essex Ambulance Service and the West Midlands Ambulance Service. These ambulance services were
representative of the types of environment typically encountered in England and included urban, mixed
urban and rural, and very rural areas. Patients with ‘respiratory symptoms’ (n= 59, one death) were
excluded, as these symptoms seemed to be less severe. There were 79 deaths in 668 patients, which
resulted in a mean mortality rate of 11.8%. This was similar to that reported in a systematic review of
15 trials of NIV in ACPO, which reported an average mortality of 10.7% (42 deaths in 389 patients).22
Thus, in the economic model a mean mortality rate of 11.8% was used with a beta distribution as shown
in Table 15.
Scenarios for cost-effectiveness analysis
The distance from hospital of patients is an important factor when considering the optimal cost-effectiveness
strategy because of the increase in mortality with increase in distance to hospital for the patient. More
specifically, it is reasonable to assume that NIV is one of the interventions that, being currently available only in
hospital, accounts for some of the association between distance and mortality. This effect of distance on
mortality of emergency admissions for respiratory illness can be observed in the large cohort of 668 patients
presenting with ‘respiratory disease’ across four ambulance services over a 4-year period from 1997 to 2001.6
This relationship can be observed in the raw data, as shown in Figure 7, which show an increase in mortality
with an increase in the distance to hospital. Appendix 8 shows mortality variation with distances, categorised
as short (< 10 km), medium (10–20 km) and long (> 20 km), with longer distances associated with
higher mortality.
TABLE 15 Mortality rates for the different scenarios
Scenario Mortality rate Distribution
General population scenario 0.118 Beta(79,589)
Rural scenario 0.141 Beta(18,109)
Urban scenario 0.110 Beta(21,166)
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In addition, the average distance to hospital and the distribution of distance to hospital for a cohort of
patients will vary according to the geographical setting of the ambulance service. For example, the distance
to hospital is greater, on average, for patients in a rural setting (South Western Ambulance Service) than
for patients in an urban setting (West Midlands Ambulance Service). Thus, with regard to pre-hospital
CPAP for patients with acute respiratory failure, we tested the model in three different scenarios:
(a) General population scenario: average distance to hospital and the distribution of distance to hospital is
that of the general population in the UK. This scenario reflects the cost-effectiveness of different
strategies at the national level.
(b) Rural population scenario: average distance to hospital and the distribution of distance to hospital is
that of a typical rural setting in the UK. This scenario reflects the cost-effectiveness of different
strategies at the rural level; thus, the services in rural areas are able to decide if this scenario and the
results best reflect their local practice.
(c) Urban population scenario: average distance to hospital and the distribution of distance to hospital is
that of a typical urban setting in the UK. This scenario reflects the cost-effectiveness of different
strategies at the urban level; thus, the services in urban areas are able to decide if this scenario and the
results best reflect their local practice.
This approach was taken because it was possible that different strategies may have different levels of
cost-effectiveness in different settings. The decision to commission pre-hospital CPAP service is typically
made at the ambulance service level and thus, the users of the results are able to decide which scenario
best reflects their local practice and if pre-hospital CPAP is a cost-effective use of resources in their setting.
For example, the cost-effectiveness of pre-hospital CPAP may be different in urban and rural areas, that is,
it is possible that it might be more cost-effective in a rural setting, where the average distance to hospital
is high, but less cost-effective in an urban setting, where the distance to hospital is not high.
The different scenarios are implemented in the model using three different baseline mortality risks: for the
general population scenario, the rural population scenario and the urban population scenario. The mortality
risk for the general population scenario is 11.8%, as described earlier in this section. The mortality rate for
South Western Ambulance Service is used as the mortality risk for the rural population scenario and the
mortality rate for West Midlands Ambulance Service is used as the mortality risk for the urban population
scenario. The mortality rates used for the different scenarios are as shown in Table 15.
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FIGURE 7 Variation in mortality with distance to hospital.
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Risk of intubation
A key secondary outcome measure of interest is the intubation rate, which is recorded as a binary
outcome. This risk of intubation for respiratory illness was modelled using the data from 3CPO study,18
a multicentre open prospective RCT of 1069 patients presenting with severe ACPO at 26 emergency
departments in the UK. The 3CPO study reported a mean intubation rate of 2.9%. This is similar to the
intubation rates of 2.7% reported in the British Thoracic Society’s National Respiratory Audit Programme
Annual Report 2011/12.86 The variance was estimated as 0.003% based on elicitation from the clinical
experts. The mean value of 2.9% and the variance was then used to calculate the α and β parameters for
a beta distribution and, thus, in the model, intubation rate is represented as a beta distribution with an
alpha of 4.45 and a beta of 150.
Effect of pre-hospital continuous positive airway pressure
Log-ORs for mortality and intubations were used as effectiveness parameters in the model for pre-hospital
CPAP. These effectiveness parameters are estimated from the meta-analysis reported in Chapter 3,
Effects of interventions. All analyses were performed using an intention-to-treat analysis, that is, all
patients and their outcomes were analysed in the groups to which they were allocated, regardless of
whether or not they received the treatment. These log-ORs parameters are assumed to be independent
of the patient’s distance from the hospital, that is, the same effectiveness parameters are applied to all
patients irrespective of how far they are from the hospital.
Effectiveness parameters of pre-hospital continuous positive airway pressure
used in the model
The ORs estimated from the NMA, as reported in Chapter 3, Effects of interventions, are used as estimates
of effectiveness for pre-hospital CPAP. The probabilities of mortality and intubation for patients given
pre-hospital CPAP were estimated by applying the log-ORs to the baseline parameters using the formulae
below. If the baseline event rate is P, then µ is estimated as logit(P)= log[P/(1 – P)]. Then the absolute
probabilities for the interventions (i.e. BiPAP and CPAP) are estimated as
P(intervention)¼ exp(µþd) / [1þ exp (µþd)], (1)
where d is the log-OR for an intervention relative to standard care estimated from the NMA.
Effect on mortality
Pre-hospital CPAP can reduce the mortality of patients as they receive the NIV earlier in the ambulance
than they would have if they had to wait to get to the hospital. The log-OR of pre-hospital CPAP for
mortality reduction is estimated from the meta-analysis reported Chapter 3, Effects of interventions.
As shown in Table 15, there is an increase in mortality with increase in distance to hospital, with the
mortality of patients > 20 km from the hospital twice as high as those < 10 km from the hospital. This
suggests that, despite the constant mortality, the absolute benefit increases as the patient’s distance from
the hospital increases, that is, patients farther from the hospital achieve more benefit from pre-hospital
CPAP than those who are closer; for example, the absolute effectiveness of pre-hospital CPAP is higher in
a rural setting than in an urban setting.
Effect on risk of intubation
The effect of pre-hospital CPAP on risk of intubation is modelled as log-OR estimated from the
meta-analysis reported in Chapter 3, Effects of interventions. This log-OR parameter is assumed to be
independent of the patient’s distance from the hospital, that is, the same risk reduction is applied to all
patients irrespective of how far they are from the hospital.
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The reduction in number of intubations leads to a reduction in the mean hospital length of stay because
mean hospital length of stay for patients without intubation is 5.84 days, compared with 10.82 days for
patients with intubation. Thus, the effect of pre-hospital CPAP on the length of hospitalisation is not
modelled as an independent relative risk to avoid double counting; it was assumed that the reduction in
the mean hospital length of stay is achieved only by reducing the number of intubations.
Long-term health outcomes
The patients who survived (i.e. who avoided the short-term mortality risk) accrued QALYs and these
lifetime QALYs are estimated based on patients’ life expectancy and their utilities.
The life expectancy of patients with acute respiratory failure admitted to hospital was captured from the
3CPO trial,18 which reported that the mean life expectancy for patients, if they were alive at 6 months,
was 3.505 years. In the 3CPO trial,18 75% of the patients were alive at 6 months and an average life
expectancy of 2 months was assumed for the remaining 25% of patients, which resulted in the mean
discounted life expectancy estimated at 2.67 years. In the model, life expectancy is parameterised as a
normal distribution with a mean of 2.67 years and standard deviation of 0.16 years, after discussions with
the clinical expert group. This is similar to the mean life expectancy reported for patients with COPD and
acute respiratory failure treated with NIV.
There was no evidence that patients who survived after receiving pre-hospital NIV experienced better
health-related quality of life than patients given standard care, so it was assumed that for a patient with
given characteristics the health-related quality of life was the same in both strategies, that is, pre-hospital
CPAP and standard care. The 3CPO study18 reported that the mean utility value was 0.6 and a variance of
0.0225% was estimated from the clinical expert group. A search for studies of survival and quality of life
after admission with pneumonia or COPD also reported similar utility values. The mean utility value and
variance were then used to calculate the α and β parameters for a beta distribution and, thus, the utility
values in the model are represented as a beta distribution with an α of 640 and a β of 425.
The estimated QALYs for patients with acute respiratory failure were estimated by multiplying the life-years
by the lifetime quality of life shown in Table 16. It was assumed that the lifetime QALYs were same for all
survivors, irrespective of whether they were in the standard care or pre-hospital CPAP arm.
Costs
The costs included in the model are:
l costs of pre-hospital CPAP
l costs of standard care
l intubation costs
l hospitalisation costs
l lifetime costs of care for patients.
Table 17 shows the average costs and their distributions included in the model. The details of how these
costs are derived are presented in the following subsections.
TABLE 16 Mean lifetime QALYs of patients
Parameter Central estimate Distribution
Mean lifetime years 2.67 years Normal(2.67,0.16)
Mean lifetime quality of life 0.6 Beta(640,425)
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Costs of standard care
The cost of standard care was assumed as £0. This simplification was made as the analysis is based on
incremental costs, that is, it was assumed that all initial treatment costs are same, regardless of whether or
not the patient gets pre-hospital CPAP. The zero costs for standard care relates only to pre-hospital and
emergency department treatment and does not include hospitalisation costs, intubation costs or additional
lifetime costs for survivors. This was deemed sensible by the expert clinical group as it was assumed that
all patients would receive NIV in hospital, irrespective of whether or not patients received pre-hospital
CPAP. This does not cause any bias even if there are different mortality rates in pre-hospital CPAP and
standard-care patients because deaths typically occur during or after emergency department treatment, so
it is reasonable to assume emergency department costs are the same regardless of mortality rate. Thus, the
only difference in treatment costs between standard care and pre-hospital CPAP was the additional costs
of pre-hospital CPAP.
Costs of pre-hospital continuous positive airway pressure
There are a number of costs involved in providing pre-hospital CPAP, such as initial equipment costs,
implementation costs and ongoing maintenance costs. These costs were converted into a cost per patient
based on a 5-year depreciation period (i.e. assuming new pre-hospital NIV equipment will be required in
5 years) and sharing the overall costs out among the number of patients that would benefit from the
service over this time period.
Number of patients receiving pre-hospital continuous positive airway pressure
in a typical ambulance service
The incidence of patients who will benefit from pre-hospital CPAP is one of the key parameters in the
model, as the unit cost of pre-hospital CPAP is estimated by dividing the total costs of pre-hospital CPAP
to the ambulance service by the number of patients treated. Estimates of this incidence vary between
sources, as shown in Table 18, and the different values are synthesised to achieve a distribution for the
costs of pre-hospital CPAP.
TABLE 17 Cost parameters used in the model
Parameter Cost (£) Distribution
Pre-hospital CPAP 1212 £1500 – £1000 × beta(2,5)
Hospitalisation costs 2250 Gamma(75,30)
Intubation costs 3500 Gamma(70,50)
Annual costs 5300 Gamma(53,100)
TABLE 18 Scenarios for unit costs of pre-hospital CPAP
Source
Incidence of eligible
patients per 100,000
Annual number of eligible
patients in an ambulance service
Unit cost (£) of
pre-hospital CPAPa
Spijker et al.77 3.5 175 1346.76
Aguilar et al.60 7.3 365 744.58
Luhr et al.87 17.8 890 417.40
Hubble et al.80 34.2 1700 309.02
BTS audit86 36.1 1800 302.40
STH ED data 40.8 2000 291.15
BTS, British Thoracic Society; STH ED, Sheffield Teaching Hospital Emergency Department.
a Using the formula unit cost= £189.93+ £202,446/n, where n is the number of patients per year.
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Spijker et al.77 reported that 16 patients received pre-hospital CPAP over an 11-month period in an ambulance
service covering a population of 500,000, which amounts to 3.5 potentially eligible cases per 100,000 per year.
This study identified only patients with ACPO, and many eligible patients did not receive treatment (which
admittedly may reflect real life), and hence this could be an underestimate of true incidence. Similarly,
Aguilar et al.60 reported that 175 patients received pre-hospital NIV across 22 months in an ambulance service
covering a population of 1.3 million, which amounts to 7.3 potentially eligible cases per 100,000 per year.
Luhr et al.87 estimated 77.6 cases of acute respiratory failure per 100,000 per year. Of these, 13.7% were
a result of COPD and 9.2% were a result of ACPO (i.e. cases with potential to benefit from pre-hospital
NIV). Thus, the incidence can be estimated as 17.8 potentially eligible cases per 100,000 per year. However,
these are relatively old data and include patients who develop acute respiratory failure in hospital, and so
may be an overestimate.
The British Thoracic Society’s National Respiratory Audit Programme Annual Report 2011/1286 reported
that 130 hospitals submitted data on 2490 patients with NIV between 1 February 2012 and 31 March
2012 (i.e. 2 months). This amounts to 19.15 patients (2490/130) per hospital per 2 months, which in
yearly terms equates to 115 patients per hospital per year. There are 168 acute hospitals in England,
serving a population of 53.01 million, which gives an incidence of 36.4 eligible cases per 100,000
population. However, the details of the audit were not clear and may be subject to bias. Furthermore,
it includes patients who develop acute respiratory failure in hospital and so may be an overestimate.
In the Sheffield Teaching Hospital emergency department, 255 sets of NIV equipment were used over
1 year. This hospital serves a population of 551,800, which equates to 46.2 potentially eligible cases per
100,000 per year. However, the equipment may not actually have been used for patient care, or multiple
pieces of equipment may have been used for the same patient, so this is likely to be an overestimate.
Hubble et al.80 estimate that 4 per 1000 patients transported by ambulance are eligible for NIV. In
2011–12 there were 4.53 million emergency ambulance transfers to a type 1 or 2 emergency department
in England (population 53.01 million). If 4 per 1000 of these patients were eligible, this suggests an
incidence of 34.2 eligible cases per 100,000 population.
Total costs of pre-hospital continuous positive airway pressure to the
ambulance service
The costs were often missing from the studies included in the review and, thus, bottom-up costing
methods were used to estimate the costs of pre-hospital CPAP. The breakdown of the costs for
pre-hospital CPAP is shown in Table 19 and is split into three main components:
1. initial costs of the pre-hospital CPAP devices
2. set-up/implementation costs (i.e. staff training costs and service reconfiguration costs)
3. maintenance costs of the service (i.e. consumables, depreciation).
The costs of the pre-hospital CPAP devices were elicited from the expert advisory group. The costs of
implementation on provider organisations were estimated using bottom-up costing methods assuming
a typical ambulance service. The maintenance costs were estimated using activity-based costing for the
resources spent on consumables based on evidence from the literature.
The pre-hospital CPAP device can take different levels of complexity and the cost of the device is based on
this complexity. For example, the costs are different for the non-invasive positive-pressure ventilation
devices and CPAP/BiPAP devices. Furthermore, the costs are also dependent on whether the devices use a
cylinder or are electrically/mechanically powered. The costs of the device were elicited from the expert
advisory group, assuming a close-fitting face mask CPAP device with Boussignac CPAP system
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manufactured by Vygon Ltd, UK, as representative of a typical CPAP system. The Boussignac hospital CPAP
kit costs £513.49 and contains the equipment required to deliver out-of-hospital CPAP. We assumed that
each ambulance would have the equipment and 10% would need to be replaced over the 5-year period.
The costs of implementation on provider organisations was estimated using bottom-up costing methods
assuming a typical ambulance service, based on the mean size of NHS ambulance services in the UK. It was
assumed that a typical ambulance service would have an average capacity of 1500 paramedics, which
was deemed sensible by the expert advisory group. The group also suggested that an average of 2 days
per year should be allocated to paramedics’ training. The costs associated with training were estimated by
multiplying this paramedic time by their daily rate according to Personal Social Services Research Unit in
2012.88 The daily cost per working day was estimated as £150 assuming an average salary of £40,000
(including overheads if they are in band 6/7) at the suggestion of the clinical advisory group. Service
reconfiguration costs were estimated as a one-off cost of £100,000, and this included the cost of
developing new guidelines/pathways. Installation costs were assumed to be zero as the CPAP system under
consideration is a disposable system.
TABLE 19 Breakdown of out-of-hospital CPAP costs
Device costs
Category Number of devices Source
Unit
cost (£) Source Total cost (£)
Out-of-hospital
CPAP device
Number of ambulances
that need the CPAP
device (420)
Expert advisory
input
513.49 Vygon Ltd, UK:
hospital CPAP kit
513.49 × 420
Assuming 10% new
CPAP devices over
5-year use (42)
Expert advisory
input
513.49 Vygon Ltd, UK:
hospital CPAP kit
513.49 × 42
Total cost of the device 237,232
Set-up/implementation costs
Category Resource use Source
Unit
cost (£) Source Total cost (£)
Initial training 1500 paramedics for
2 days each
Expert advisory
input
150 per
day
Expert advisory
input
450,000
Service
reconfiguration
One-off cost for
reconfiguration
Expert advisory
input
100,000
Total set-up/implementation costs 550,000
Maintenance costs
Category Resource use Source
Unit
cost (£) Source Total cost (£)
Consumables Number of patients
over 5 years= 5 × n
Expert advisory
input
189.93
per use
Vygon Ltd, UK:
facial mask, oxygen
tubing and valve
189.93 × 5 × n
Ongoing
training
1500 paramedics for
1 day each
Expert advisory
input
150 per
day
Expert advisory
input
225,000
Total maintenance costs 225,000+ 949.65 × n
Total costs
Total costs of out-of-hospital CPAP 1,012,232+ 949.65 × n
Total number of patients [n patients per year × depreciation period of 5 years (i.e. assuming new
out-of-hospital CPAP equipment will be required in 5 years)]
5 × n
Cost of out-of-hospital CPAP per patient 189.93+ 202,446/n
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The maintenance costs were estimated using costing for the resources spent on consumables based on
information from the manufacturers that the facial mask, oxygen tubing and valve (costing £189.93)
would need to be replaced after each use, while the rest of the equipment was reusable. The expert
advisory group suggested that an average of 1 additional day half-way through the 5-year period will be
required by paramedics to update their training.
Scenarios for costs of pre-hospital continuous positive airway pressure to the
ambulance service
As seen above, estimates of incidence reported in different sources are substantially different; they are
summarised in Table 18. A typical ambulance service caters for a population of around 5 million, which
suggests a range from around 175 to 2000 patients per ambulance service in a year depending on the
estimate of the incidence. Thus, scenario analysis was conducted by estimating the unit cost for providing
pre-hospital CPAP for these different estimates of the eligible population. In addition, this information was
synthesised into an expression for the pre-hospital CPAP costs as £1500 – £1000 × β(2,5). This was chosen
because our clinical experts believed that most of the samples of costs will fall between £1400 and £800,
with only a few instances when the costs are lower than £800.
Three different cost scenarios were analysed alongside the baseline analysis:
1. A high-cost scenario assumed 170 patients per year would be eligible for pre-hospital CPAP with a unit
cost of £1400.
2. A low-cost scenario assumed 365 patients per year would be eligible for pre-hospital CPAP with a unit
cost of £745.
3. A lower-cost scenario assumed 1700–2000 patients per year would be eligible for pre-hospital CPAP
with a unit cost of £300.
Hospitalisation costs
A further main outcome included in the model is the cost of stay associated with hospitalisations. The
hospitalisation stay is dependent on whether or not the patient needs intubation, because length of stay is
longer for patients who undergo intubation. Hubble et al.80 report that the mean hospital length of stay
for patients without intubation is 5.84 days. This is similar to the mean length of stay for patients with
respiratory failure in the UK, estimated as the weighted average of 8801 patients associated with DZ27D
and DZ27E (respiratory failure without intubation with major complications and comorbidity, and
respiratory failure without intubation with intermediate complications and comorbidity) reported in the
NHS Reference Costs 2011–2012.89 Thus, the mean inpatient admission cost for hospitalisations was
calculated as the weighted average of the costs of patients with DZ27D and DZ27E, from the NHS
Reference Costs 2011–2012.89 The hospitalisation cost used in the model, with a mean cost of £2400,
is represented as a gamma distribution with an α of 80 and a β of 30.
Intubation costs
The cost of intubation was estimated as a one-off cost. Although costs for the DZ27A and DZ27B
(respiratory failure with intubation with major complications and comorbidity, and respiratory failure with
intubation with intermediate complications and comorbidity) were reported in the NHS Reference Costs
2011–2012,89 they were based on a small sample size of 180 patients across the UK whose average total
length of stay is 7 days, that is, an additional 1.2 days for intubation. The clinical expert group deemed
this as not representative and suggested using the data from Hubble et al.80 to estimate the costs of
intubation. Hubble et al.80 report a mean hospital length of stay of 10.82 days for patients with intubation
(i.e. approximately an additional 5 days for intubation compared with patients without intubation) and it
was assumed that 5 additional hospital days spent by the intubated patients will be in the intensive care
unit, based on the suggestions by the clinical expert group.
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Thus, the cost of intubation was estimated by multiplying intensive care unit costs of £700 per day80 by the
average length of stay for intubation, assumed to be 5 days, which results in a mean cost of intubation of
£3500. The cost of intubation used in the model is represented as a gamma distribution with an
α of 70 and a β of 50.
Lifetime costs of care
Lifetime costs of survivors were estimated using the annual costs and the discounted life expectancy of
patients captured from the 3CPO trial.18 The 3CPO study reported that the mean cost in months 4–6 was
£1341, which resulted in mean annual costs of £5300. In the model, the annual cost is parameterised as
a gamma distribution with an α of 53 and a β of 100, after discussions with the clinical expert group.
It was assumed that the lifetime costs were the same for all survivors, irrespective of whether they were in
the standard care or pre-hospital CPAP arm.
Summary of modelling input parameters
The decision-analytic model assigned to each patient a baseline probability of death and intubation. The
risks of death and intubation for pre-hospital CPAP were estimated by applying the ORs from the
meta-analysis to the baseline risks of mortality and intubation. Each patient alive then accumulated costs
and QALYs based on the cost parameters, life expectancy and utility values. A summary of the model
parameters is provided in Table 20.
TABLE 20 Summary of model parameters
Parameter Mean Distribution Source
Baseline risks
Scenario analysis: distribution of 30-day mortality risk
General population mean 30-day mortality probability 0.118 Beta(79,589) Nicholl et al.6
Rural scenario mean 30-day mortality probability 0.141 Beta(18,109) Nicholl et al.6
Urban scenario mean 30-day mortality probability 0.110 Beta(21,166) Nicholl et al.6
Baseline risks
Risk of intubation 0.029 Beta(4.45,150) 3CPO,18 clinical opinion
OR for pre-hospital CPAP
Mortality OR 0.43 Samples NMA
Intubation OR 0.32 Samples NMA
Life expectancy of patients
Lifetime years 2.67 years Normal(2.67,0.16) 3CPO,18 clinical opinion
Health-related quality of life
Utility 0.6 Beta(640,425) 3CPO,18 clinical opinion
Costs (£)
Pre-hospital CPAP 1212 1500 – 1000 × beta(2,5) Clinical input
Hospitalisation 2250 Gamma(75,30) NHS reference costs89
Intubation 3500 Gamma(70,50) NHS reference costs89
Annual costs 5300 Gamma(53,100) NHS reference costs89
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Methods to estimate cost-effectiveness
The cost-effectiveness of the different interventions was estimated using both the incremental cost-effectiveness
ratio (ICER) and the net benefit approaches. Uncertainty was incorporated in the modelling by performing
probabilistic sensitivity analysis. Descriptions of these terms and approaches are provided in the following
sections: Definitions of cost-effectiveness terms, Uncertainty analysis and Value of information analysis.
Definitions of cost-effectiveness terms
The ICER measures the relative value of two strategies and is calculated as the mean incremental cost
divided by the mean incremental benefits. A strategy is dominated when another strategy accrues more
QALYs for less cost. Extended dominance occurs when a combination of two alternative strategies can
produce the same QALYs as a chosen strategy but at a lower cost. Strategies that are neither dominated
nor extendedly dominated constitute the cost-effectiveness frontier, and the ICER is reported for these
strategies compared with the next least effective strategy. The willingness-to-pay threshold is the amount
of money that the decision-maker is willing to pay to gain one additional QALY. The usual threshold for
decision-making at NICE is considered to be around £20,000–30,000 per QALY. The net monetary benefit
is defined as the QALYs multiplied by a value for the QALYs (e.g. £20,000) minus the costs of obtaining
them, that is, net monetary benefit= (QALYs × λ) – cost, where λ is the willingness-to-pay threshold. The
net monetary benefit approach is simpler to calculate and gives equivalent findings (but requires an explicit
assumption regarding the value of λ).
Uncertainty analysis
The results presented in the following section include the effects of accounting for uncertainty in the
model parameters (the costs, utilities, risks and ORs for mortality and intubation), characterised as
probability distributions. Probabilistic sensitivity analysis is undertaken whereby the model is rerun
(1000 times), each time with a different value for the risks, ORs, costs and utilities, which are sampled
from the probability distributions. The cost-effectiveness plane shows the incremental costs (y-axis) and
incremental QALYs (x-axis) compared with usual care. In this chart, if a model run for a strategy had
exactly the same costs and QALYs as usual care then the ‘sample’ for that model run would appear at the
origin. Samples plotted to the right of the y-axis have more QALYs than usual care and samples plotted
above the x-axis have more costs. Samples plotted to the right of a straight line with slope λ passing
through the origin are cost-effective, whereas those plotted to the left are not. The cost-effectiveness
acceptability curve (CEAC) shows the proportion of model runs for which each strategy is cost-effective
over a range of potential willingness-to-pay thresholds (i.e. λ).
Another measure of uncertainty is the overall EVPI. This calculation is carried out based on the theory that
the decision-maker will choose the most cost-effective option but could acquire additional evidence to
reduce the uncertainties in the decision, for example, know exactly what the HRs for mortality and
hospitalisations are for each treatment. In the EVPI calculation, it can be estimated how often making the
decision based on current evidence could be wrong, and also how many QALYs (and costs) would be lost
by choosing the strategy that is expected to be most cost-effective given current evidence, when in fact
one of the other strategies is truly the most cost-effective. The monetary value lost by making a ‘wrong’
decision to choose a strategy based on current evidence can be estimated by valuing the QALYs using the
willingness-to-pay threshold for this possible loss, that is, the net benefit lost on each of the occasions
when another strategy would be optimum. This can be multiplied by the number of patients per year and
the expected lifetime of the decision to estimate the population EVPI.
Value of information analysis
The interpretation of population EVPI is that, if one could fund research to eliminate the uncertainty in
effectiveness for all of the parameters for each strategy (e.g. by a large or infinitely large clinical trial), then the
value of eliminating the uncertainty through such research would be expected to be the population EVPI.
This can be thought of as the maximum that the health-care system should be willing to pay for additional
evidence to inform the decision in the future and, thus, is an upper bound on the value of conducting further
research, that is, if the population EVPI exceeds the expected costs of additional research then it is potentially
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cost-effective to conduct further research. However, EVPI, defined as the maximum investment a
decision-maker would be willing to pay to eliminate all parameter uncertainty from the decision problem,
has the limitation that it assumes that all information can be determined with certainty.
Expected value of partial perfect information (EVPPI) is similar to EVPI, but instead of evaluating the
uncertainty associated with all parameters it focuses on the uncertainty associated with a subset of one of
more parameters, allowing the decision-makers to be able to conclude in which variables further research
would be most beneficial. The computational time required for EVPPI is markedly more than for EVPI as the
process essentially requires two iterations of probabilistic analyses, as standard probabilistic sensitivity
analyses are undertaken for each sampled parameter value for the variable(s) under analysis. If the
population EVPPI for a subset of parameters exceeds the expected costs of additional research, then it is
potentially cost-effective to conduct further research to estimate those parameters.
Expected value of sample information addresses the limitation that values for the parameters can be
ascertained without uncertainty, which effectively assumes an infinite trial size, and seeks to provide an
optimal number of patients to study within a future trial. In addition, EVSI also allows the evaluation of
marginal returns with an increased sample size formally taken into account (e.g. that an additional
100 patients, when only 500 have been recruited, would be likely to provide more value than when
20,000 have been recruited). Within EVSI the costs of the trial are compared with the benefits achieved
in order to find the maximum expected net benefit of sampling, which would correspond with the
recommended trial size. If the population EVSI of a proposed trial is greater than the costs of the trial, then
it is cost-effective to conduct the trial to address the uncertainty. EVSI, similarly to EVPPI, requires two
iterations of probabilistic analyses and, additionally, the updating of prior information with the simulated
results of the future trial to form a posterior distribution.
Results of the independent economic assessment
This section details the results of the cost-effectiveness analyses estimated for a single patient as mean
values of 1000 probabilistic sensitivity analysis runs, each run with a different estimate for the risks, ORs,
costs and utilities sampled from the probability distributions reported in Table 20. The expected estimates
of cost-effectiveness and the uncertainty around them are presented, along with the probability that each
of the strategies, pre-hospital CPAP and standard care, is the most cost-effective. The EVPI, a measure of
how valuable it would be to eliminate all of the existing uncertainty, is also provided.
Results of the base-case scenario
The results of the NMA suggested that pre-hospital CPAP is effective in terms of reducing mortality and
intubations as the mean ORs (calculated as an average of the 1000 samples provided by the NMA for
input into the model) are less than one. However, pre-hospital CPAP is also more expensive than standard
care with mean additional costs of around £1200 for pre-hospital CPAP. Thus, it is necessary to estimate
the incremental cost-effectiveness compared with the other interventions to answer the question, ‘Is the
additional effect estimated for pre-hospital CPAP worth the additional costs of the strategy?’
The QALY results suggest that the lower OR for mortality would result in an estimated QALY gain for
pre-hospital CPAP over standard care of 0.099 QALYs (mean QALYs= 1.513 for pre-hospital NIV compared
with 1.414 QALYs for standard care). The expected costs over a lifetime also differ, with pre-hospital CPAP
having higher costs (£16,895) than usual care (£14,863). The majority of this cost difference of £2032
was a result of the difference in the costs of treatment, that is, the cost of pre-hospital CPAP and the
higher long-term costs, which were dependent on the number of people alive and their annual costs.
To assess whether or not the additional costs are worthwhile, the incremental cost per QALY gained
is estimated. Comparing pre-hospital CPAP with standard care, the incremental cost per QALY gained is
£2032/0.076= £20,514 per QALY, which is just above the typical NICE threshold of £20,000 per QALY gained.
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Another way to present these results is to calculate the net monetary benefit of each strategy. The net
monetary benefit of pre-hospital CPAP is (1.513 × £20,000) – £16,895= £13,365. This approach takes away
the need to calculate the ICER and simplifies the interpretation for decision-makers as the strategy with the
highest expected incremental net monetary benefit is the most cost-effective. Using a threshold value of
£20,000 per QALY, the estimated incremental net monetary benefit of pre-hospital CPAP compared with
standard care is estimated to be £13,365 – £13,419= –£54. Mathematically, as this difference is negative
(i.e. < 0), the ICER must be > £20,000 (the ICER of pre-hospital CPAP compared with standard care is £20,514
per QALY).
As the model is rerun 1000 times, each time with a different value for the OR, costs and utilities sampled
from the probability distribution, in some of the sampled model runs standard care could be more effective
than pre-hospital CPAP because of the uncertainty in the probability distributions of ORs. In the
cost-effectiveness plane shown in Figure 8, the samples to the right of the diagonal line through the origin
would have an incremental cost per QALY compared with usual care of < £20,000 and so would be
considered cost-effective compared with usual care. Figure 8 shows that the samples fall almost equally on
either side of the diagonal line, suggesting that there is uncertainty in stating that pre-hospital CPAP has a
chance of being cost-effective compared with standard care. The uncertainty in costs shown in Figure 8 is
actually a function of the uncertainty in the mortality ORs (more or less time alive, during which there is a
cost per year). The mean ICER, presented as the blue triangle in cost-effectiveness plane of Figure 8, is just
above the £20,000 per QALY threshold line which is in line with our estimated mean ICER of £20,514 per QALY.
The CEAC in Figure 9 shows the proportion of model runs for which each strategy is cost-effective over a
range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital CPAP
was the most cost-effective strategy (at a £20,000 per QALY threshold) was 49.5%, with the percentage
of model runs in which usual care was the most cost-effective being the rest, 50.5%. This was also
observed in Figure 8, where the samples fall almost equally on either side of the diagonal line, that is,
there is approximately a 50% chance of being cost-effective at a threshold of £20,000 per QALY. A CEAC
in which the best strategy is cost-effective only half of the time indicates that there is uncertainty as to
which strategy is optimum in terms of net benefit.
Results for different geographical scenarios
The results seen in the base-case scenario are for the UK general population scenario and reflect the
cost-effectiveness of different strategies at the national level, that is, the average distance to hospital and
the distribution of distance to hospital are those of the general population in the UK. However, the
distance to hospital is greater, on average, for patients in a rural setting (e.g. South West Ambulance
Service) than in an urban setting (e.g. West Midlands Ambulance Service) and, to this end, we tested the
model in two other scenarios:
1. Rural population scenario: the average distance to hospital and the distribution of distance to hospital
are those of a typical rural setting in the UK. This scenario reflects the cost-effectiveness of different
strategies at the rural level; thus, the services in rural areas are able to decide if this scenario and the
results best reflect their local practice.
2. Urban population scenario: the average distance to hospital and the distribution of distance to hospital
are those of a typical urban setting in the UK. This scenario reflects the cost-effectiveness of different
strategies at the urban level; thus, the services in urban areas are able to decide if this scenario and the
results best reflect their local practice.
The mortality rates used for the different scenarios are shown in Table 15. This approach was taken
because it is possible that different strategies may have different levels of cost-effectiveness in different
settings. The decision to commission a pre-hospital CPAP service is typically made at the ambulance service
level and, thus, the users of the results are able to decide which scenario best reflects their local practice
and if pre-hospital CPAP is a cost-effective use of resources in their setting. A summary of the results for
the two scenarios, compared with the base-case scenario, is presented in Table 21.
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It can be seen that the cost-effectiveness of pre-hospital CPAP is different in urban and rural areas,
that is, pre-hospital CPAP in a rural setting is more cost-effective as the average distance to hospital is high
and pre-hospital CPAP can help save more lives but is not as cost-effective in an urban setting where
the mortality is low as the distance to hospital is not high. The results are presented in more detail in the
following sections Results of rural scenario and Results of urban scenario.
Results of rural scenario
The QALY results suggest that the higher baseline mortality in the rural setting combined with the same
relative effectiveness of pre-hospital CPAP would result in a higher estimated QALY gain for pre-hospital
CPAP over standard care of 0.117 QALYs (mean QALYs= 1.494 for pre-hospital CPAP compared with
1.377 QALYs for standard care). This is because of the higher baseline mortality risk in the rural scenario,
which, combined with same mortality ORs of pre-hospital CPAP, results in more lives saved, which leads to
more QALYs gained compared with the base-case scenario. The expected costs over a lifetime also differ,
with pre-hospital CPAP having higher costs (£16,724) than usual care (£14,540). Comparing pre-hospital
CPAP with standard care, the incremental cost per QALY gained is £2184/0.117= £18,744 per QALY,
which is below the typical NICE threshold of £20,000–30,000 per QALY gained.
This can also be observed in the mean ICER, presented as a blue triangle in the cost-effectiveness plane of
Figure 10, as it is just below the £20,000 per QALY threshold line (which is in line with our estimated
mean ICER of £18,744 per QALY). The cost-effectiveness plane in Figure 10 shows that the majority of the
samples fall to the right of the diagonal line, suggesting that pre-hospital CPAP has a higher chance of
being cost-effective than usual care.
The CEAC in Figure 11 shows the proportion of model runs for which each strategy is cost-effective over a
range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital
CPAP was the most cost-effective strategy (at a £20,000 per QALY threshold) was 58.8%, which again
indicates less uncertainty as to which strategy is optimum in terms of net benefit.
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FIGURE 10 Cost-effectiveness plane for the rural population scenario.
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Results of urban scenario
The QALY results suggest that the higher baseline mortality in the urban setting, combined with the same
relative effectiveness of pre-hospital CPAP, would result in a lower estimated QALY gain for pre-hospital
CPAP over standard care of 0.093 QALYs (mean QALYs= 1.520 for pre-hospital NIV, compared with 1.427
QALYs for standard care). This is because of the lower baseline mortality risk in the urban scenario, which,
combined with same mortality ORs of pre-hospital CPAP, results in fewer lives saved, which leads to fewer
QALYs gained. The expected costs over a lifetime also differ, with pre-hospital CPAP having higher costs
(£16,950) than usual care (£14,971). Comparing pre-hospital CPAP with standard care, the incremental
cost per QALY gained is £1979/0.093= £21,284 per QALY, which is above the typical NICE threshold
of £20,000 per QALY gained.
This can also be observed in the mean ICER, presented as a blue triangle in the cost-effectiveness plane of
Figure 12, as it is above the £20,000 per QALY threshold line (in line with our estimated mean ICER of
£21,284 per QALY). The cost-effectiveness plane in Figure 12, shows that only a minority of the samples
fall to the right of the diagonal line, suggesting that the chance of pre-hospital CPAP being cost-effective
compared with usual care is lower than in the base-case scenario.
The CEAC in Figure 13 shows the proportion of model runs for which each strategy is cost-effective over
a range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital
CPAP was the most cost-effective strategy (at a £20,000 per QALY threshold) was 41.5%, which indicates
greater uncertainty as to which strategy is optimum in terms of net benefit.
Results for different cost scenarios
Scenario analysis was also conducted for three different estimates of the unit (per patient) cost of
performing pre-hospital CPAP (for different proportions of the eligible population): a high-cost scenario
with a unit cost of £1400, a low-cost scenario with a unit cost of £745 and a lower-cost scenario with
a unit cost of £300. These estimates relate to the capability of the ambulance services to deliver the
pre-hospital CPAP service at these costs and the users of the results are able to decide which scenario
best reflects their local practice and if pre-hospital CPAP is a cost-effective use of resources in their setting.
A summary of the results for the three scenarios, compared with the base-case scenario, is presented in
Table 22.
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As expected, the cost-effectiveness of pre-hospital CPAP improves as the unit costs become lower. This is
because the QALY gain for pre-hospital CPAP over standard care of 0.099 QALYs (mean QALYs= 1.513
for pre-hospital CPAP compared with 1.414 QALYs for standard care) remains the same while the
expected costs over a lifetime go down (as a result of the lower costs of pre-hospital CPAP).
Results of high-cost scenario
The expected costs over a lifetime are higher in this scenario, with the cost of pre-hospital CPAP being
higher, at £17,078, than that of standard care (£14,863), a cost difference of £2215. This is higher than
the incremental costs in the base-case scenario, where the cost difference is £2032 (pre-hospital CPAP
costs of £16,895, compared with a usual care cost of £14,863). This variation is due to the difference in
the costs of pre-hospital CPAP in the high-cost scenario and the base-case scenario. In this high-cost
scenario, the incremental cost per QALY gained is £2216/0.099= £22,368 per QALY, which is above the
typical NICE threshold of £20,000 per QALY gained, as shown by the blue triangle in the cost-effectiveness
plane in Figure 14. The cost-effectiveness plane in Figure 14 shows that the only a minority of the samples
fall to the right of the diagonal line, suggesting that pre-hospital CPAP has a low chance of being
cost-effective compared with usual care.
The CEAC in Figure 15 shows the proportion of model runs for which each strategy is cost-effective over a
range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital CPAP
was the most cost-effective strategy (at a £20,000 per QALY threshold) was 35.4%, which indicates
increased uncertainty that pre-hospital CPAP is optimum in terms of net benefit. This was also observed in
Figure 14, where most of the samples fall on left side of the diagonal line, that is, there is only a one-third
chance of pre-hospital CPAP being cost-effective at a threshold of £20,000 per QALY.
Results of low-cost scenario
The expected costs over a lifetime are lower than in the base-case scenario, with the cost of pre-hospital
CPAP being £16,421, compared with £14,863 for usual care and, comparing pre-hospital CPAP with
standard care, the incremental cost per QALY gained is £1558/0.099= £15,728 per QALY, which is below
the typical NICE threshold of £20,000 per QALY gained, suggesting that it is cost-effective. The
cost-effectiveness plane for the high-cost scenario is shown in Figure 16.
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FIGURE 14 Cost-effectiveness plane for the high-cost scenario.
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The CEAC in Figure 17 shows the proportion of model runs for which each strategy is cost-effective over a
range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital CPAP
was the most cost-effective strategy (at a £20,000 per QALY threshold) was 79.8%, which indicates
greater confidence to state that pre-hospital CPAP is optimum in terms of net benefit.
Results of lower-cost scenario
The expected costs over a lifetime for this scenario are even lower, with the costs of pre-hospital CPAP
being £15,977, compared with £14,863 for standard care, that is, pre-hospital CPAP incurs additional
costs of £1114 compared with standard care. This is much lower than the incremental cost in the
base-case scenario, which is £2032 (pre-hospital CPAP costs of £16,895 compared with usual care costs of
£14,863), and this variation is a result of the lower costs of pre-hospital CPAP in this scenario than in the
base-case scenario.
The incremental cost per QALY gained is £1114/0.099= £11,248 per QALY, which is much lower than the
typical NICE threshold of £20,000 per QALY gained, suggesting that pre-hospital CPAP is cost-effective, as
shown in the cost-effectiveness plane in Figure 18. The cost-effectiveness plane in Figure 18 shows that
the majority of the samples fall to the right of the diagonal line, suggesting that pre-hospital CPAP has a
high chance of being cost-effective compared with usual care.
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FIGURE 16 Cost-effectiveness plane for the low-cost scenario.
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The CEAC in Figure 19 shows the proportion of model runs for which each strategy is cost-effective over a
range of potential willingness-to-pay thresholds. The percentage of model runs in which pre-hospital CPAP
was the most cost-effective strategy (at a £20,000 per QALY threshold) was 93.8%, which indicates a
much greater confidence to state that pre-hospital CPAP is optimum in terms of net benefit.
Costs and benefits for a typical NHS ambulance service
To present the results of the economic analysis in a way that may be more meaningful for decision-makers,
we estimated the annual additional costs and lives saved that would be expected across a typical
ambulance service if pre-hospital CPAP were implemented. These estimates were highly dependent on the
estimated incidence of patients likely to benefit from pre-hospital CPAP, so they are presented in Table 23
according to the annual number of eligible patients expected by an ambulance service covering a
population of 5 million.
The annual costs and lives saved obviously vary according to the number of eligible patients, but if a typical
ambulance service treated 175 appropriate patients per year it could save 10.81 lives while incurring
£235,683 additional costs, whereas if a typical ambulance service treated 2000 appropriate patients per
year it could save 123.52 lives while incurring £582,300 additional costs.
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FIGURE 18 Cost-effectiveness plane for the lower-cost scenario.
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Value of information analyses
The uncertainty in the base-case analysis can also be measured as the overall EVPI, which is the average
of the net benefits lost by making the decision to choose pre-hospital CPAP. The individual patient EVPI for
the base-case model is illustrated in Figure 20. At low thresholds for cost-effectiveness, additional
information is unlikely to change that decision. The EVPI reaches maximum when there is most uncertainty
about whether to adopt or reject the technology based on existing evidence, that is, at a threshold of
around £20,000 per QALY. The EVPI for the base-case analysis at a threshold of £20,000 per QALY is
£184 per patient for whom the decision is made. EVPI for the whole population can be estimated as EVPI
per patient multiplied by the number of patients affected by the decision over the lifetime of the
technology, that is, multiplying the EVPI by incidence over the lifetime of the technology. However, as
reported in the previous section, Costs of pre-hospital continuous positive airway pressure, there is
uncertainty regarding incidence as different estimates of incidence are reported in different sources. Thus,
population EVPI was estimated at higher and lower values of incidence to reflect this uncertainty. The
lifetime of the technology was assumed to be 5 years and the total population of England and Wales to
be 60 million.
Assuming an annual incidence of 3.5 per 100,000 population, the number of respiratory failure patients
eligible for pre-hospital CPAP in England and Wales can be estimated as 2100 and, with a lifetime of 5 years
for the technology, the population EVPI at the threshold of £20,000 per QALY is £184 × 2100 × 5= £1.9M.
If an annual incidence of 40.8 per 100,000 is assumed, then the population EVPI is £22.5M.
Expected value of partial perfect information
Partial EVPI provides the value of reducing the uncertainty surrounding particular input parameters in the
decision model, and this can be used to identify the parameters for which more precise estimates would
be most valuable to focus further research.
The EVPPIs associated with the parameters are illustrated in Figure 21. At the threshold of £20,000 per
QALY, EVPPIs associated with ‘baseline mortality’, ‘pre-hospital CPAP mortality effectiveness’ and ‘total
costs of pre-hospital CPAP’ are £14.85, £156.12 and £37.54, respectively. Other parameters do not come
out of the analysis as substantial, as shown in Figure 21. In addition, the combined EVPPI for the three
parameters (i.e. ‘baseline mortality’, ‘pre-hospital CPAP mortality effectiveness’ and ‘total costs of
pre-hospital CPAP’) is £174.61, which is close to the overall EVPI; this suggests that most of the
uncertainty in the model is due to the uncertainty in these three parameters.
The high EVPPIs associated with the three parameters above suggest that further experimental research to
estimate these parameters will potentially be cost-effective. EVPPI for the whole population can be
estimated as EVPPI per patient multiplied by the number of patients affected by the decision over
the lifetime of the technology. Assuming an annual incidence of 3.5 per 100,000 population, the
undiscounted population EVPPI for the three parameters (i.e. ‘baseline mortality’, ‘pre-hospital CPAP
TABLE 23 Annual costs and lives saved across a typical NHS ambulance service
Annual number of
eligible patients
Annual cost
of service (£)
Annual number of deaths
with standard care
Annual number of deaths
with pre-hospital CPAP
Annual number
of lives saved
175 235,683 20.79 9.98 10.81
365 271,772 43.37 20.82 22.54
890 371,486 105.75 50.78 54.97
1700 525,334 201.99 96.99 105.00
1800 544,320 213.87 102.70 111.17
2000 582,300 237.63 114.11 123.52
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mortality effectiveness’ and ‘total costs of pre-hospital CPAP’) at the threshold of £20,000 per QALY is
£180 × 2100 × 5= £1.83M. If an annual incidence of 40.8 per 100,000 is assumed, then the population
EVPPI is £21.3M.
Expected value of sample information
Expected value of sample information seeks to provide an optimal number of patients to study within
a future trial by comparing the costs of the trial with the benefits achieved in order to find the
recommended trial size. For any given set of parameters, EVSI values are always lower than partial EVPPI
values and hence EVSI analysis was conducted only for ‘baseline mortality’, ‘pre-hospital CPAP mortality
effectiveness’ and ‘total costs of pre-hospital CPAP’, as the EVPPI values for other parameters are not
significant (i.e. further experimental research to estimate other parameters may not be cost-effective). The
EVSI values were estimated for a RCT conducted to estimate the ‘baseline mortality’ and ‘pre-hospital
CPAP mortality effectiveness’ and the analysis was carried out for different sample sizes in order to
estimate the optimal trial size.
It should also be noted that the trial has benefits other than EVSI as, for example, it also allows the
estimation of the incidence of cases eligible for pre-hospital NIV, the costs of setting up and running
the service, and determining whether or not a large trial would be feasible. This suggests that the EVSI will
be higher than that reported in Table 24. If we assume that the trial will also address the uncertainty in
the cost of pre-hospital CPAP, then an additional EVSI of £35.56 per patient can be added on top of the
original EVSI.
If the population EVSI of a proposed trial at a given sample size is greater than the costs of the trial, then it
is cost-effective to conduct the trial to address the uncertainty. For example, it is cost-effective to do a trial
with 100 patients in each arm (trial 4) if the overall cost is less than £1.08M or £12.67M, depending on
which source of incidence is more believable. If an incidence of 40 patients per 100,000 population is to
be believed, then there is a clear argument for conducting a trial, as the expected benefits of the trial
outweigh the costs of conducting such a trial.
0
20
40
60
80
100
120
140
160
180
EV
PP
I p
er
 p
at
ie
n
t
Input parameters
Ba
se
lin
e m
or
ta
lit
y
Ba
se
lin
e i
nt
ub
at
io
n
Lo
g-
OR
 m
or
ta
lit
y
Lo
g-
OR
 in
tu
ba
tio
n
Co
st 
of
 p
re
-h
os
pi
ta
l C
PA
P
Ho
sp
ita
lis
at
io
n 
co
sts
In
tu
ba
tio
n 
co
sts
Co
sts
 p
er
 ye
ar
Lif
e e
xp
ec
ta
nc
y
Ut
ilit
y
FIGURE 21 Individual patient EVPPI at £20,000 per QALY.
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TABLE 24 Expected value of sample information for different trial sizes
Trial identifier Number per arm EVSI per patient
Population EVSI:
low estimate (£)
Population EVSI:
high estimate (£)
1 10 31.30 328,669 3,831,336
2 30 67.91 713,106 8,312,777
3 50 83.28 874,454 10,193,636
4 100 103.52 1,086,960 12,670,848
5 150 114.53 1,202,602 14,018,903
6 250 126.56 1,328,855 15,490,654
7 350 133.30 1,399,688 16,316,362
8 650 142.95 1,500,975 17,497,080
9 1000 148.25 1,556,625 18,145,800
10 2000 154.12 1,618,260 18,864,288
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness review
Pre-hospital CPAP appears to be an effective treatment for acute respiratory failure, with evidence that it
reduces mortality (OR 0.41, 95% CrI 0.20 to 0.77) and intubation rate (OR 0.32, 95% CrI 0.17 to 0.62)
compared with standard care. The effectiveness of pre-hospital BiPAP is uncertain, with estimates of the
effect on mortality (OR 1.94, 95% CrI 0.65 to 6.14) and intubation rate (OR 0.40, 95% CrI 0.14 to 1.16)
including the possibility of either worthwhile benefit or considerable harm. These findings suggest that
pre-hospital CPAP may have a beneficial role in reducing mortality and intubation rates in acute respiratory
failure, whereas there is currently insufficient evidence to determine the role of pre-hospital BiPAP.
The NMA using both IPD and aggregate data suggested that male sex was a significant treatment effect
modifier of mortality, with CPAP being more effective in males. The pathological basis of these findings is
not clear, so they should be interpreted with caution. We found no such associations in the analysis of
intubation data.
Economic evaluation
The economic analysis showed that pre-hospital CPAP was more effective than standard care, with 0.099
QALYs gained per patient treated, but was more expensive, with an additional cost of £2032 per patient
treated. The ICER for pre-hospital CPAP was £20,514 per QALY compared with standard care, with 49.5%
probability of being cost-effective at the £20,000 per QALY threshold. These findings suggest that, even if
the apparent effectiveness of pre-hospital CPAP suggested by our meta-analysis were confirmed, it is
uncertain whether or not widespread implementation of pre-hospital CPAP would represent a worthwhile
use of NHS resources.
Sensitivity analysis showed that, compared with the general population scenario, pre-hospital CPAP was
more likely to be cost-effective in an ambulance service covering a rural population (ICER £18,744 per
QALY, 58.8% probability of being cost-effective at the £20,000 per QALY threshold) and less likely to be
cost-effective in an ambulance service covering an urban population (ICER £21,284 per QALY, 41.5%
probability). So, although pre-hospital CPAP is most likely to be cost-effective in an ambulance service
covering a rural population, there is substantial uncertainty regarding cost-effectiveness in each scenario.
While developing the economic model, we identified marked variation between estimates from different
sources of the incidence of patients likely to benefit from pre-hospital CPAP. Sensitivity analysis also
showed that this parameter was an important determinant of cost-effectiveness. The lower estimate of
incidence resulted in a higher cost per patient (£1400), a high ICER (£22,368 per QALY) and a low
probability of being cost-effective (35.4% at the £20,000 per QALY threshold). The higher estimate of
incidence resulted in a lower cost per patient (£300), a lower ICER (£11,248 per QALY) and a high
probability of being cost-effective (93.8% at the £20,000 per QALY threshold). Our analysis suggested that
if a typical ambulance service treated 175 appropriate patients per year it could save 10.81 lives while
incurring £235,683 additional costs, whereas if a typical ambulance service treated 2000 appropriate
patients per year it could save 123.52 lives while incurring £582,300 additional costs.
The incidence of appropriate patients was also an important determinant of the expected value of
information. The population EVPI is £1.9M at a low estimate of incidence and £22.5M at a higher incidence.
EVPPI analysis suggested that ‘pre-hospital CPAP mortality effectiveness’, ‘total costs of pre-hospital CPAP’
and ‘baseline mortality’ are the key parameters with EVPPI values of £156.12, £37.54 and £14.85 per
patient, respectively. Population EVPPI for the three parameters together at the threshold is estimated as
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£1.83M at low incidence and £21.3M at a higher incidence. Similarly, population EVSI value for a RCT with
100 patients in each arm to estimate ‘baseline mortality’ and ‘pre-hospital CPAP mortality effectiveness’ is
estimated as £1.08M at low incidence and £12.67M at a higher incidence. If the population EVSI of a
proposed trial at a given sample size is greater than the costs of the trial, then it is cost-effective to conduct
the trial to address the uncertainty. A trial of pre-hospital CPAP would probably cost between £1.08M and
£12.67M, so the value of undertaking a trial would depend on the anticipated incidence of appropriate
patients. Feasibility of a trial would also, logically, depend on this parameter, so it appears that a reliable
estimate of the incidence of eligible patients is an essential prerequisite to further randomised evaluation.
Strengths and limitations of the assessment
Clinical effectiveness review
Four previous systematic reviews35,36,38,90 have evaluated the role of pre-hospital NIV in treating ACPO or
acute respiratory failure, but only one of these undertook a meta-analysis.90 Williams et al.90 evaluated the
effectiveness of pre-hospital CPAP for acute respiratory failure and identified three randomised trials,47,48,53
a non-randomised comparative study74 and a retrospective comparative study.67 The three randomised
trials47,48,53 were all included in our meta-analysis. The two non-randomised studies67,74 were identified and
included in our description of non-randomised studies but not included in our meta-analysis. We included
two additional recent randomised trials in our meta-analysis.46,52 We also included a trial of early versus late
pre-hospital CPAP50 in our main analysis but excluded it from our sensitivity analysis. This trial was excluded
by Williams et al.90
The meta-analysis undertaken by Williams et al.90 included randomised and non-randomised studies and
reported that CPAP was associated with lower mortality (OR 0.41, 95% CI 0.19 to 0.87) and fewer
intubations (OR 0.31, 95% CI 0.19 to 0.51). These ORs are very similar to ours (mortality OR 0.41,
95% CrI 0.20 to 0.77; intubation rate OR 0.32, 95% CrI 0.17 to 0.62), suggesting that the results are driven
by the three trials47,48,53 that were included in both analyses, which together contributed 400 patients. The
inclusion of non-randomised studies in the meta-analysis by Williams et al.90 may be inappropriate, given their
high risk of bias. Our decision to include quasi-randomised trials54,55 could also be criticised for similar reasons.
Meanwhile, our decision to include the trial by Plaisance et al.50 could be questioned, given that the control
group in this trial received delayed pre-hospital NIV. However, our sensitivity analysis with these studies
excluded produced very similar results to the main analysis.
Our review was more comprehensive than previous reviews and, by excluding non-randomised trials from
meta-analysis, carried a lower risk of bias. Non-randomised trials were reported to describe outcomes only
when pre-hospital NIV is used in non-trial settings. Although we are confident that we have identified
and included all existing randomised trials, it is possible that unregistered trials exist and have not been
reported. The validity of our findings is principally dependent on the validity of the primary data. The
included studies were of reasonably high quality, the main threats to validity were the lack of blinding of
outcome measurement and lack of adequate sample size. Lack of blinding is unlikely to have influenced
mortality, but could have influenced intubation rates. A clinician might be more eager to initiate intubation
in a patient is receiving no ventilator support than in one with similar respiratory parameters who is
receiving NIV. However, from a pragmatic perspective, this apparent bias could be seen as part of the
effect of NIV. If the provision of NIV results in less use of intubation then, pragmatically, it does not matter
whether this is achieved by improving respiratory function or by encouraging the clinician to withhold
intubation while medical treatment takes effect.
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Meta-analysis is intended to overcome the lack of statistical power to detect potentially worthwhile
differences in mortality and intubation rates in the primary studies. However, this is inevitably still limited
by the sample sizes of the primary studies. We therefore cannot conclude that BiPAP is ineffective and the
wide CIs suggest that we should not pay too much attention to the apparent direction of effect on
mortality, with BiPAP appearing to increase mortality.
It is possible that the control groups in the trials did not all receive best alternative care and that this may have
inflated the potential benefit of pre-hospital NIV. In-hospital NIV is widely available in most developed health
services and one would expect that any patient eligible for pre-hospital NIV would receive in-hospital NIV if
treatment were not available pre hospital. However, only one trial mandated the use of in-hospital NIV, while
one prohibited its use, three allowed its use and five did not record this information.
Our analysis is also limited by a lack of generalisability, particularly to the UK. The trials were generally
small (n= 23–207) and might represent selected patient groups. However, the trial reported mortality and
intubation rates that were similar to those in non-randomised studies, while uncontrolled studies of
pre-hospital NIV reported intubation and mortality rates that were, if anything, higher. This suggests that
trials were not selecting patients at a higher risk of adverse outcome compared with non-randomised and
observational studies.
None of the trials was undertaken in the UK. Pre-hospital systems vary substantially between countries and
the trial settings were often very different from the UK. Pre-hospital NIV in the UK would probably be
provided by paramedics working independently (i.e. without online medical control), whereas in the
trials pre-hospital NIV was provided by specialist units which included physicians in six trials,47,48,50–52,55
paramedics in three49,53,54 and the provider was not reported in one.46 Only two of the trials51,52 recruited
patients with undifferentiated acute respiratory distress, while six46–48,50,54,55 recruited patients with
presumed ACPO. It is not clear how ACPO would have been reliably diagnosed in the pre-hospital setting,
although physicians may have more training and experience, to allow them to make this judgement, than
paramedics. Finally, additional monitoring technology such as near-patient arterial blood gas analysis,
which is not available to UK ambulance services, was used in five studies.47,28,50,51,55
Generalising the findings from small trials of selected patients to routine practice can be potentially
misleading. Meta-analysis of small studies of in-hospital NIV for ACPO22,23 concluded that treatment was
effective and likely to reduce mortality and intubation rates. However, a subsequent large pragmatic trial
of in-hospital NIV for ACPO18 found only modest improvements in breathlessness and acidosis, with no
significant effect on mortality and intubation rates.
The combined IPD and aggregate data meta-analysis allowed an investigation of the potential for patient-level
characteristics to be treatment effect modifiers. The use of IPD makes use of data from all patients rather than
resorting to a meta-regression of aggregate data based on a limited number of studies.
Individual patient-level data were not available from all studies and we used a combination of IPD and
aggregate data. The combined IPD and aggregate data meta-analyses were conducted separately for each
potential treatment effect modifier. Ideally, we would incorporate all covariates into a single model but this
was not possible because some studies did not provide data on all covariates. It is a limitation of the
combined IPD and aggregate data meta-analyses that were conducted that the studies included in
the analyses depended on the availability of data on each covariate in each study.
Economic evaluation
We identified only one previous economic evaluation80 of pre-hospital NIV for patients with acute
respiratory failure that fulfilled our inclusion criteria. As described in Chapter 4, Cost-effectiveness review
summary, this study had a number of limitations that prevented reliable conclusions being drawn
regarding the cost-effectiveness of pre-hospital NIV in the NHS. It used in-hospital effectiveness data rather
than pre-hospital data; outcomes were valued as lives saved rather than QALYs; the setting was the
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US health-care system and US cost estimates were used; the model only used a 1-year time horizon and
probabilistic sensitivity analysis was not performed. We therefore undertook an analysis that addressed all
these limitations.
Our analysis took the economic perspective of the NHS in England and Wales, was based on effectiveness
estimates from our meta-analysis of pre-hospital CPAP for acute respiratory failure, valued outcomes as
QALYs, used a lifetime horizon and included probabilistic sensitivity analysis. Other strengths included
detailed costing at the level of the ambulance service and then estimated on a per-patient basis using a
range of estimates for the incidence of eligible patients; use of relevant existing data sources to estimate
key population, cost and outcome parameters; and scenario analysis involving urban and rural
ambulance services.
Despite these strengths, our analysis had some limitations. As previously discussed, the estimates of
effectiveness of pre-hospital NIV were derived from our meta-analysis of small trials, involving potentially
selected study populations, that might not have compared pre-hospital CPAP to best alternative care and
were undertaken in settings that differ markedly from the NHS. Meta-analysis suggested that pre-hospital
CPAP reduces mortality and intubation rates, but if these findings are not reproduced in the NHS then
pre-hospital CPAP will not be cost-effective.
The cost per patient of providing pre-hospital CPAP is calculated by dividing the total cost of setting up
and running the service by the total number of patients treated. This means that the cost per patient is
determined by the incidence of patients who are likely to benefit from pre-hospital CPAP. We identified a
number of different sources for our estimate of this parameter but these estimates varied markedly.
Sensitivity analysis showed that cost per patient is an important determinant of cost-effectiveness so an
accurate estimate of the incidence of patients likely to benefit from pre-hospital CPAP is required to
accurately estimate cost-effectiveness.
We assumed that all patients receiving pre-hospital CPAP would have this treatment continued in hospital and,
that, in the absence of pre-hospital CPAP, all potentially treated patients would receive pre-hospital NIV. This
assumption is unlikely to hold in practice. However, it is reasonable to assume that if pre-hospital CPAP is used
in additional patients who are unlikely to really need it then this will only incur a small additional cost (since
most of the costs of pre-hospital CPAP are accrued in setting up the service) and no significant additional
benefit, so this will not markedly affect overall cost-effectiveness.
Uncertainties
Although our meta-analysis appears to show that pre-hospital CPAP is an effective treatment for acute
respiratory failure, the reliability of this conclusion is limited by the issues outlined in the previous section,
Strengths and limitations of the assessment. Evidence derived from synthesising multiple small trials
should ideally be confirmed in a large pragmatic trial. None of the trials was undertaken in the UK, the
intervention was delivered by physicians in most trials and the trial populations might have been a selected
subset of all those presenting with acute respiratory failure. Further research is required to determine if
pre-hospital NIV can be delivered by NHS paramedics and if the effectiveness of pre-hospital CPAP is
confirmed in these circumstances.
Our estimates of the effectiveness of pre-hospital BiPAP were subject to substantial uncertainty and include
the possibility of worthwhile benefit and significant harm. A large pragmatic trial would help to resolve this
uncertainty but this is unlikely, unless a strong theoretical case can be made for favouring BiPAP over
CPAP, since pre-hospital CPAP appears to be more feasible in the NHS and is supported by more
promising data.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Economic analysis showed that the cost-effectiveness of pre-hospital CPAP is uncertain, with an ICER close
to the £20,000-per-QALY threshold and 49.5% probability of being considered cost-effective at this
threshold. Sensitivity analysis showed that these findings were dependent on the incidence of patients
likely to benefit from pre-hospital CPAP and, to a lesser extent, whether the ambulance service covers a
rural or urban population. Accurate estimation of the incidence of suitable patients is required to better
estimate cost-effectiveness.
Expected value of information analysis was undertaken to explore uncertainty and determine the value
of further research. It showed that the value of undertaking a trial depends on the estimated incidence of
eligible patients. The maximum cost at which it would be cost-effective to carry out a trial with 100 patients
in each arm is only £1.08M if there is a low estimated incidence of eligible patients, but is £12.67M if there
is a high estimated incidence. A more precise estimate of the incidence of eligible patients is therefore
required to determine the cost-effectiveness of a future trial of pre-hospital CPAP in the NHS.
Other relevant factors
Our meta-analysis suggests that pre-hospital CPAP is effective for acute respiratory failure but provides no
evidence that BiPAP is effective. This should not be interpreted as providing evidence that pre-hospital CPAP
works while pre-hospital BiPAP does not. A meta-analysis91 and a large trial92 comparing in-hospital CPAP to
BiPAP for ACPO showed no significant differences in clinical outcomes. There was substantial uncertainty
around the estimates of effectiveness of BiPAP and these include the possibility of worthwhile benefit. Our
decision to use CPAP as the modality for pre-hospital NIV in the economic analysis was based on the
practicalities of delivering pre-hospital NIV in a paramedic-based system rather than selection on the basis
of effectiveness.
Assessment of factors relevant to the NHS and other parties
Acute respiratory failure is the common pathway for some of the most frequent causes of in-hospital death.
Our analysis has shown that pre-hospital CPAP may reduce mortality from acute respiratory failure.
However, this does not mean that large numbers of patients are eligible to be treated by pre-hospital CPAP.
Its effectiveness is likely to be limited to selected patients with a reversible underlying cause who are
transported to hospital by emergency ambulance and are severely ill, such that supplemental oxygen and
medical therapy will be inadequate and the delay incurred prior to receiving in-hospital NIV could be critical.
We identified a number of sources to estimate the incidence of such cases, but none was ideal, and there
was substantial variation between estimates. As noted earlier, this is important because the incidence of
patients likely to benefit from CPAP has a powerful impact on cost-effectiveness. Perhaps more
fundamentally, this parameter determines how important the whole issue of pre-hospital NIV is to the NHS.
The configuration of emergency medical care in the NHS is an important and related factor. Centralisation
of services can improve outcomes for patients with myocardial infarction, stroke and major trauma, but
may increase the distance that patients have to travel to hospital. This may increase the risk of death for
some patient groups, particularly those with respiratory diseases and especially acute respiratory failure.
We modelled the effect of increasing the distance travelled to hospital by comparing the general
population scenario to an urban scenario with shorter distances and to a rural scenario with longer
distances. Unsurprisingly, given the assumptions of our model, pre-hospital CPAP was more effective and
thus more cost-effective in the rural scenario. However, variation in cost-effectiveness was modest and,
in all three scenarios tested, the cost-effectiveness of pre-hospital CPAP compared with standard care
remained uncertain with an ICER close to the £20,000 per QALY threshold. It therefore appears that,
although any reconfiguration that increases the distance travelled to hospital could increase the potential
need for pre-hospital CPAP, it is not likely to have a major impact on our estimates of cost-effectiveness.
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As highlighted in Strengths and limitations of the assessment, all the trials of pre-hospital NIV were
undertaken in pre-hospital systems that may differ markedly from the NHS. Most involved physicians
delivering pre-hospital NIV, and those involving paramedics typically had some form of online support.
Further research is required to determine the effectiveness of pre-hospital NIV delivered by independently
working paramedics, which would represent typical practice in the NHS. In the economic analysis, we
assumed that pre-hospital CPAP was more likely to be feasible in the NHS and would be delivered by
widespread training of paramedics and equipping of ambulances. This approach is expensive but has the
advantage of ensuring maximal coverage of the population. Alternative approaches could be used
involving a smaller number of critical care paramedics using rapid response vehicles. This would be
potentially cheaper but would require accurate targeting of patients eligible for pre-hospital NIV. There is
currently no research available to determine whether or not this would be possible, so this approach
carries a substantial risk that only a minority of patients who could benefit from pre-hospital CPAP would
actually receive it.
If the model of delivering pre-hospital CPAP used in our analysis is adopted it will incur substantial up-front
costs for training paramedics and equipping ambulances. Reducing hospital length of stay may offset
some of these costs, and the overall additional costs may be justified by improved outcomes, but further
research is required to determine this. Even if pre-hospital CPAP were shown to be cost-effective it would
still require substantial up-front funding, which would involve either allocation of additional resources to
ambulance services or reallocation from within the ambulance service budget.
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Chapter 6 Conclusions
Implications for service provision
The available evidence suggests that pre-hospital CPAP is associated with reduced mortality and reduced
intubation rates for patients with acute respiratory failure compared with standard care. However, this
evidence has a number of limitations that may have led to overestimation of effectiveness, and the
findings of the meta-analysis may not be generalisable to the NHS. Furthermore, pre-hospital CPAP can be
effectively delivered only if ambulances are appropriately equipped and paramedics are properly trained.
We estimated that setting up and running pre-hospital CPAP across an ambulance service covering a
population of 5 million would cost between £235,683 and £582,300 per year. This means that any
recommendation to implement pre-hospital CPAP needs to be based on evidence of cost-effectiveness as
well as effectiveness.
Economic analysis suggested that cost-effectiveness is uncertain and is dependent on our estimates of
effectiveness being realised in practice and that there is a sufficient pool of patients who would receive
and benefit from pre-hospital CPAP. Current evidence is therefore insufficient to recommend the
implementation of pre-hospital CPAP in the NHS. Further evidence of feasibility, effectiveness and
cost-effectiveness in the NHS is required. It has been suggested that in the past pre-hospital and emergency
medicine practitioners may have adopted new technologies before rigorous evaluation.93 It may therefore
be wise to recommend that use of pre-hospital CPAP in the NHS should be limited to the research setting.
Although BiPAP has theoretical benefits compared with CPAP, the available evidence is much weaker and
does not currently support the use of pre-hospital BiPAP. The equipment and training required to deliver
BiPAP may make this more difficult to deliver in the NHS. Further research into pre-hospital BiPAP is
therefore desirable, but the practical advantages and more promising existing data for CPAP mean that
future research efforts are likely to be better focused on pre-hospital CPAP.
Suggested research priorities
A large pragmatic trial with associated economic analysis could determine if pre-hospital CPAP is a
clinically effective and cost-effective treatment for acute respiratory failure in the NHS. The trial would need
to be large enough to detect a modest but potentially worthwhile difference in mortality. It would also
need to compare pre-hospital CPAP with best alternative care, which in most cases would involve
in-hospital NIV, and would need to be powered to explore effectiveness in subgroups with different
transport times to hospital, such as rural and urban populations. However, our expected value of
information analysis suggested that a trial costing several million pounds would only be cost-effective if
the incidence of eligible patients was towards the higher end of our range of estimates. A more precise
estimate of this parameter is therefore required before a trial can be recommended.
The incidence of eligible patients is also an important determinant of the feasibility of a trial. Estimates
used in our economic analysis suggest that a typical paramedic may, on average, see an eligible patient
less often than once per year. Such a low frequency may make reliable identification and recruitment
difficult. Pre-hospital care is a challenging environment in which to recruit and randomise patients.94 NHS
paramedics currently have little experience of recruiting to trials or providing pre-hospital CPAP. A trial
would be feasible only if there were sufficient eligible patients to support a reasonable recruitment rate
and if these patients could be recruited and randomised in the challenging pre-hospital environment.
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We therefore recommend a feasibility study of pre-hospital CPAP in one ambulance service to determine
the incidence of patients transported by emergency ambulance who are eligible for pre-hospital CPAP.
If randomised, this study could also determine the feasibility of a trial and explore barriers to recruitment.
Updating our economic model with a more accurate estimate of the incidence of eligible patients
would reduce the uncertainty surrounding our estimate of the cost-effectiveness of both a trial of
pre-hospital CPAP and the cost-effectiveness of pre-hospital CPAP itself. If the feasibility study showed
that pre-hospital CPAP could be appropriately delivered in the NHS with an incidence of use towards the
higher end of our estimates, and showed that recruitment and randomisation were feasible, then a large
pragmatic trial to determine clinical effectiveness and cost-effectiveness could be recommended.
CONCLUSIONS
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Appendix 1 Literature search strategies for the
review of clinical effectiveness: a MEDLINE example
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE
Provider: OvidSP.
Date range searched: from 1948 to August 2013.
Date of search: August 2013.
1. non-invasive ventilation.ti,ab.
2. non invasive ventilation.ti,ab.
3. noninvasive ventilation.ti,ab.
4. NIV.ti,ab.
5. non-invasive positive pressure ventilation.ti,ab.
6. non invasive positive pressure ventilation.ti,ab.
7. noninvasive positive pressure ventilation.ti,ab.
8. NIPPV.ti,ab.
9. exp Positive-Pressure Respiration/
10. exp Continuous Positive Airway Pressure/
11. continuous positive airway pressure.ti,ab.
12. CPAP.ti,ab.
13. bi-level positive airway pressure.ti,ab.
14. bi level positive airway pressure.ti,ab.
15. bilevel positive airway pressure.ti,ab.
16. BIPAP.ti,ab.
17. non-invasive ventilatory support.ti,ab.
18. non invasive ventilatory support.ti,ab.
19. noninvasive ventilatory support.ti,ab.
20. bag-valve-mask ventilat$.ti,ab.
21. bag valve mask ventilat$.ti,ab.
22. bvm.ti,ab.
23. or/1-22
24. pre-hospital.ti,ab.
25. pre hospital.ti,ab.
26. prehospital.ti,ab.
27. exp Ambulances/
28. ambulance$.ti,ab.
29. community.ti,ab.
30. out of hospital.ti,ab.
31. before hospital.ti,ab.
32. (prior adj5 hospital).ti,ab.
33. paramedic$.ti,ab.
34. exp Emergency Medical Services/
35. emergency medical service$.ti,ab.
36. emergency care.ti,ab.
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37. emergency health service$.ti,ab.
38. ems.ti,ab.
39. exp Ambulatory Care/
40. ambulatory care.ab,ti.
41. mobile intensive care unit$.ti,ab.
42. micu.ti,ab.
43. mobile intensive care ambulance$.ti,ab.
44. mica$.ti,ab.
45. Emergency Medical Technicians/
46. paramedic$.ab,ti.
47. (emergency adj3 technician$).ab,ti.
48. emt.ab,ti.
49. or/24-48
50. 23 and 49
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Appendix 2 Methodological assessment
(adapted) criteria for randomised controlled trials
Criteria Criteria met Criteria defined (if applicable)
1 Was the method used to assign
participants to the treatment groups
really random?
Yes Computer-generated random numbers, random number
tables, random-permuted blocks, sealed assignment,
sequentially numbered sealed opaque envelopes
No Use of alternation, case record numbers, date of birth or
days of the week
Unclear Insufficient detail to make judgement
2 Was the allocation of treatment
concealed?
Yes Allocation to each group performed adequately (e.g.
centrally, sequentially numbered, sealed opaque envelopes)
No Group assignment based on day of admission, case record
numbers, date of birth or day of the week, open random
number lists, non-opaque sealed envelopes
Unclear Insufficient detail to make judgement
3 Were the outcome assessors/data
analysts blinded to the treatment
allocations (it was not considered
plausible that patients could
be blinded to these types of
interventions)?
Yes Independent outcome assessors and data analysts were
blinded to which group the patient belongs to
No Outcomes assessed and data analysed by those involved in
the intervention, or those who are aware of group
membership
Unclear Insufficient detail to make judgement
4 Were the eligibility criteria for study
entry specified?
Yes Eligibility criteria for study entry specified
No Eligibility criteria for study entry not specified
Unclear Insufficient detail to make judgement
5 Was baseline comparability achieved
for the most important prognostic
indicators?
Yes The baseline characteristics of each study group (in particular
age, diagnosis and/or physiological characteristics) were
clearly outlined and any differences identified were
accounted for
No The baseline characteristics (in particular age, diagnosis
and/or physiological characteristics) of each study group were
not outlined or accounted for
Unclear Insufficient detail to make judgement
6 Adequate follow-up of patients
(at least 80%)
Yes Proportion and characteristics of those participants lost to
follow-up (≤ 20%) clearly reported for each group and
outcome. A clear outline is provided as to how losses of
participants were handled
No Proportion and characteristics of those participants lost to
follow-up more than 20%. No clear outline is provided as to
how losses of participants were handled
Unclear Insufficient detail to make judgement
7 Were the reasons for withdrawal
stated?
Yes Reasons for withdrawal were stated
No Reasons for withdrawal were not stated
Unclear Insufficient detail to make judgement
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Criteria Criteria met Criteria defined (if applicable)
8 Was an intention-to-treat analysis
included?
Yes All patients assigned to one of the treatments are analysed
together, regardless of whether or not they completed or
received that treatment
No All patients assigned to one of the treatments are not
analysed together, regardless of whether or not they
completed or received that treatment (e.g. per protocol)
Unclear Insufficient detail to make judgement
9 Was the study powered to detect
differences in outcomes?
Yes A power calculation was performed and reported. The study
was adequately powered to detect differences in outcomes
No A power calculation was not performed. A power calculation
was performed and reported but the study was not
adequately powered to detect differences in outcomes.
A power calculation was performed but not reported, the
study states it was adequately powered to detect differences
in outcomes
Unclear Insufficient detail to make judgement
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Appendix 3 Network meta-analysis model and
sensitivity analyses
We let rik be the number of events out of the total number of patients in each arm, nik, for arm k andtrial i. We assume that the data follow a binomial distribution such that:
rik∼Binomial(nik, pik), (2)
where pik represents the probability of an event in arm k of trial i.
We use the logit link function to map the probabilities on to the real line. We then define:
logit(pik) = μi þ δi, 1kIfk≠1g, (3)
where
Ifug =

1 if u is true
0 otherwise:
(4)
The μi are trial-specific baselines representing the log-odds of an event in the control treatment, and the
δi,1k are the trial-specific log–ORs of an event in the treatment group relative to the control.
We assume that the trial-specific treatment effects of the treatment in arm k, relative to the control
treatment (in arm 1), are drawn from a common random-effects distribution such that:
δi, 1k∼N(dti1, tik, τ2), (5)
where dti1, tik represents the population effect of the treatment in arm k in trial i, tik, compared with
the treatment in arm 1 of trial i, ti1, and τ2 represents the between-trial variance in treatment
effects (heterogeneity).
The basic parameters for the treatment effects are d1t, the effect of treatment t (t= BiPAP, CPAP) relative
to the reference treatment 1 (defined as usual care).
The model is completed by giving the trial-specific baselines, the basic parameters and the between-trial
standard deviations prior distributions such that:
μi∼N(0,1000)
d1t∼N(0,1000)
τ∼HN(0, 0:16).
(6)
The prior distribution for τ has mean 0.32 and 95% CrI 0.01 to 0.91. This suggests that we believe, a
priori, that it is most likely there is mild heterogeneity in intervention effects between trials, but that we
allow for the possibility that there could be moderate to extreme heterogeneity in intervention effects
between trials.
The common reference prior distribution that is used for the between-trials standard deviation, and the
one that we used in our initial analysis, is a uniform (U) prior distribution on the interval 0 to 2, that is,
U(0,2). This means that we believe a priori that there may be extreme heterogeneity in intervention effects
between trials, and the range of plausible values means that the heterogeneity could be huge.
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There appeared to be relatively little Bayesian updating of the prior distribution to the posterior distribution
of the between-trials standard deviation (probably as a consequence of there being relatively few studies).
Given that prior distributions should reflect genuine prior beliefs unless there is a reasonable number of
sample data, or else posterior distributions will not reflect genuine posterior beliefs, we used a half-normal
(HN) prior distribution [i.e. HN(0,0.16)] in our main analyses. Results of the analyses using a U(0,2) prior
distribution are presented below.
TABLE 25 Mortality in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds of
death relative to usual care (standard oxygen therapy) (random effects) using a HN(0,0.16) prior distribution
for the between-trials standard deviation
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 1.89 0.48 to 7.18 1.91 0.21 to 17.15 0.000
CPAP 0.38 0.13 to 0.91 0.39 0.05 to 2.51 1.000
Usual carea
Reference Reference Reference Reference Reference 0.000
Between-study standard deviation 0.61 0.04 to 1.71 – – –
a Usual care defined as standard oxygen therapy with conventional medical treatment.
TABLE 26 Intubation rates in pre-hospital NIV patients with acute respiratory failure: posterior results for the odds
of intubation relative to usual care (standard oxygen therapy) (random effects) using a HN(0,0.16) prior
distribution for the between-trials standard deviation
Treatment
Random-effects mean Predictive distribution
Probability most
effectiveOR 95% CrI OR 95% CrI
NIV
BiPAP 0.42 0.12 to 1.51 0.42 0.06 to 2.97 0.352
CPAP 0.32 0.14 to 0.77 0.32 0.06 to 1.82 0.647
Usual carea
Reference Reference Reference Reference Reference 0.001
Between-study standard deviation 0.43 0.03 to 1.62 – – –
a Usual care defined as standard oxygen therapy with conventional medical treatment.
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Appendix 4 Network meta-analysis model
including treatment effect modifiers
Let j be the study where j= 1,. . ., NSIPD, and NSIPD is the number of IPD studies included in the NMA.Let yijk= 1 if the ith patient in the jth study on treatment k experiences the event and yijk= 0 if the ith
patient in the jth study on treatment k does not experience the event, where i= 1,. . . . , Nj, such that Nj is
the number of patients in the jth study. Assume that the outcomes of patients yijk, are independent and
identically distributed as yijk∼ Bernoulli (pjk), where pjk is the probability of an event for a patient in the jth
study on treatment k. The settings for the aggregate data studies are the same as in Appendix 6, except
for the mortality discrepancies noted in Chapter 3, Network meta-analysis using combined individual
patient-level data and aggregate data.
Suppose βXY is the regression coefficient for the interaction for the comparison of treatment Y relative to
treatment X. The regression coefficients corresponding to the basic parameters (e.g. βAB, βAC) are estimated
by the model and are used to estimate the remaining regression coefficient (e.g. βBC= βAC – βAB).
The likelihood function for IPD studies is:
logit(pi jk)=

µjb þ β0 jbxi jk if k = b, b ∈ fA, B, Cg
µjb þ β0 jbxi jk þ δ jbk þ (βAk−βAb)xi jk if k≻b, (7)
where βAA= 0; j= 1,. . . , NSIPD; xik is a patient-level covariate for the ith patient in the jth study on treatment k;
and β0jb is a study-specific regression parameter that represents the difference in the log-odds of an event in
treatment group b per unit increase in the covariate.
The likelihood function for aggregate data studies is:
logit(pjk)=

λ jb if k = b, b ∈ fA, B, Cg
λ jb þ δ jbk þ (βAk−βAb)z j if k≻b, (8)
where βAA= 0 and j= (NSIPD+ 1),. . ., (NSIPD+NSAD).
The study-specific treatment effect δjbk is assumed from the following distribution.
δ jbk∼N(dbk, τ2)=N(dAk−dAb, τ2), (9)
where dAA= 0, dbk represents the mean log-OR of k versus b when the covariate value is zero
(i.e. xijk= zj= 0) and τ2 represents the between-trial variance in treatment effects (heterogeneity).
The regression coefficient βAk is assumed to be exchangeable:
βAk∼N(mB, τ
2
B). (10)
The model is completed by giving the trial-specific baselines, the basic parameters and the between-trial
standard deviations prior distributions such that:
µi∼N(0,1000)
d1t∼N(0,1000)
τ∼HN(0, 0:16).
(11)
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Appendix 5 Clinical effectiveness review: table of
excluded studies with rationale
Author, year Reason for exclusion
Aguilar et al., 201159 (abstract) Non-randomised observational study (full paper reported in Aguilar et al. 2013)60
Aguilar et al., 201360 Non-randomised observational study
Fort PA, 201256 Ongoing study (VeNIS BPCO trial) – due for completion in December 2014
Austin et al., 201395 Original abstract included (multiple report)
Baker, 198396 Review/comment/editorial
Baker, 200597 Review/comment/editorial
Berteloot et al., 2011 (abstract)61 Non-randomised observational study
Bledsoe et al., 201262 Non-randomised observational study
Bohanske et al., 201098 Observational study with no relevant outcome data
Bott et al., 199399 In-hospital NIV (RCT)
Bruge et al., 200863 Non-randomised observational study
Bultman et al., 200564 (abstract) Non-randomised observational study
Cheskes et al., 2012100 Observational study with no relevant outcome data
Confalonieri et al., 1999101 In-hospital NIV (RCT)
Crawford et al., 2008102 In-hospital NIV (RCT)
Cuny et al., 2013 (abstract)65 Non-randomised observational study
Derr et al., 200666 Non-randomised observational study
Dib et al., 201267 Non-randomised observational study
Dieperink et al., 200968 Non-randomised observational study
Ducros et al., 2008103 (abstract) Full peer-reviewed paper included
Foti et al., 200969 Non-randomised observational study
Freitas et al., 201070 (abstract) Non-randomised observational study
Fyntanidou et al., 200971 (abstract) Non-randomised observational study
Gardtman et al., 2000104 Observational study with no relevant intervention
Garuti et al., 201072 Non-randomised observational study
Gonzva et al., 2013105 Observational study with no relevant outcome data
Goss, 2008106 Review/comment/editorial
Goss and Zygowiec, 2006107 Review/comment/editorial
Grosomanidis et al., 200073 (abstract) Non-randomised observational study
Hastings et al., 1998108 Review/comment/editorial
Soo Hoo et al., 1994109 In-hospital NIV (observational study)
Hubble et al., 200674 Non-randomised observational study
Kallio et al., 200375 Non-randomised observational study
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Author, year Reason for exclusion
Kelly et al., 2002110 In-hospital NIV (RCT)
Klemen et al., 2009111 Observational study with no relevant intervention
Kosowsky and Zane, 2001112 Review/comment/editorial
Kosowsky et al., 200176 Non-randomised observational study
Lightner et al., 2010113 Review/comment/editorial
Lobato et al., 2012114 Review/comment/editorial
Maraffi et al., 2009115 In-hospital NIV (RCT)
Mattera, 1998116 Review/comment/editorial
Moritz et al., 2003117 In-hospital NIV (RCT)
Navalesi and Pollini, 2000118 Review/comment/editorial
Oliver and Narayanan, 2013119 Review/comment/editorial
Roggla et al., 2013120 Review/comment/editorial
Soma et al., 2008121 In-hospital NIV (RCT)
Spijker et al., 201377 Non-randomised observational study
Taylor et al., 2008122 Observational study with no relevant intervention
Templier et al., 2002123 Observational study with no relevant outcome data
Templier et al., 200378 Non-randomised observational study
Templier et al., 2011124 Review/comment/editorial
Templier et al., 2012125 Observational study with no relevant outcome data
Thys et al., 2002126 In-hospital NIV (RCT)
Valipour et al., 2004127 In-hospital NIV (observational study)
Warner, 201079 Non-randomised observational study
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Appendix 6 Summary of trials included in the
base-case network meta-analysis of pre-hospital
non-invasive ventilation for acute respiratory failure
Author, year
Number of intubations Mortality (within 30 days)
Intervention Control Intervention Control
Events Total Events Total Events Total Events Total
Studies evaluating CPAP
Austin and Wills, 201246 (abstract) NR NR NR NR 1 24 9 26
aDucros et al., 201147 3 107 6 100 8 107 9 100
aFrontin et al., 201148 2 60 3 62 6 60 7 62
aPlaisance et al., 200750 6 63 16 61 2 63 8 61
Schmidbauer et al., 201152 3 18 7 18 0 18 0 18
aThompson et al., 200853 7 35 17 34 5 35 12 34
Studies evaluating BiPAP
aMas et al., 200249 (abstract) 3 28 1 28 6 28 2 28
aRoessler et al., 201251 1 24 6 25 1 24 2 25
bCraven et al., 200054 4 37 7 25 6 37 2 24
a,bWeitz et al., 200755 NR NR NR NR 1 10 1 13
NR, not reported.
a Authors provided IPD data.
b Quasi-controlled trials.
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Appendix 7 Literature search strategies for the
review of cost-effectiveness: a MEDLINE example
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R)
Provider: OvidSP.
Date range searched: from 1948 to August 2013.
Date searched: August 2013.
1. non-invasive ventilation.ti,ab.
2. non invasive ventilation.ti,ab.
3. noninvasive ventilation.ti,ab.
4. NIV.ti,ab.
5. non-invasive positive pressure ventilation.ti,ab.
6. non invasive positive pressure ventilation.ti,ab.
7. noninvasive positive pressure ventilation.ti,ab.
8. NIPPV.ti,ab.
9. exp Positive-Pressure Respiration/
10. exp Continuous Positive Airway Pressure/
11. continuous positive airway pressure.ti,ab.
12. CPAP.ti,ab.
13. bi-level positive airway pressure.ti,ab.
14. bi level positive airway pressure.ti,ab.
15. bilevel positive airway pressure.ti,ab.
16. BIPAP.ti,ab.
17. non-invasive ventilatory support.ti,ab.
18. non invasive ventilatory support.ti,ab.
19. noninvasive ventilatory support.ti,ab.
20. bag-valve-mask ventilat$.ti,ab.
21. bag valve mask ventilat$.ti,ab.
22. bvm.ti,ab.
23. or/1-22
24. pre-hospital.ti,ab.
25. pre hospital.ti,ab.
26. prehospital.ti,ab.
27. exp Ambulances/
28. ambulance$.ti,ab.
29. community.ti,ab.
30. out of hospital.ti,ab.
31. before hospital.ti,ab.
32. (prior adj5 hospital).ti,ab.
33. paramedic$.ti,ab.
34. exp Emergency Medical Services/
35. emergency medical service$.ti,ab.
36. emergency care.ti,ab.
DOI: 10.3310/hta19420 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 42
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
37. emergency health service$.ti,ab.
38. ems.ti,ab.
39. exp Ambulatory Care/
40. ambulatory care.ab,ti.
41. mobile intensive care unit$.ti,ab.
42. micu.ti,ab.
43. mobile intensive care ambulance$.ti,ab.
44. mica$.ti,ab.
45. Emergency Medical Technicians/
46. paramedic$.ab,ti. (5008)
47. (emergency adj3 technician$).ab,ti.
48. emt.ab,ti.
49. or/24-48
50. 23 and 49
51. Economics/
52. “costs and cost analysis”/
53. Cost allocation/
54. Cost-benefit analysis/
55. Cost control/
56. cost savings/
57. Cost of illness/
58. Cost sharing/
59. “deductibles and coinsurance”/
60. Health care costs/
61. Direct service costs/
62. Drug costs/
63. Employer health costs/
64. Hospital costs/
65. Health expenditures/
66. Capital expenditures/
67. Value of life/
68. exp economics, hospital/
69. exp economics, medical/
70. Economics, nursing/
71. Economics, pharmaceutical/
72. exp "fees and charges"/
73. exp budgets/
74. (low adj cost).mp.
75. (high adj cost).mp.
76. (health?care adj cost$).mp.
77. (fiscal or funding or financial or finance).tw.
78. (cost adj estimate$).mp.
79. (cost adj variable).mp.
80. (unit adj cost$).mp.
81. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
82. or/51-81
83. 50 and 82
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Appendix 8 Effect of distance on mortality
The effect of distance on mortality of emergency admissions for respiratory illness can be observed in thelarge cohort data set of 668 patients who presented with ‘respiratory disease’ across four ambulance
services over a 4-year period from 1997 to 2001. This relationship can be observed in the raw data, which
shows an increase in mortality with an increase in the distance to hospital. The relationship between
ambulance journey time and mortality of emergency admissions for respiratory disease was also modelled
but no clear pattern was observed. This could be because journey times depend on the accuracy and
consistency with which times of leaving the scene and arrival at hospital are recorded, and they can also
be affected by ‘reverse causation’, which occurs when the patient’s condition is a cause of the journey
time rather than vice versa, such as when ambulances drive as fast as possible to hospital for critically ill
patients but slowly and with less risk for patients not critically ill.
Table 27 below shows mortality variation with distances, categorised as short (< 10 km), medium
(10–20 km) and long (> 20 km), with longer distances associated with higher mortality. The results match
the original analysis for patients with respiratory disease.6
The split of patients by distance in the different scenarios are shown in Table 28. For each scenario, the
overall mortality rate is estimated by multiplying by the probability of death in each distance category by
the proportion of patients in that distance category.
TABLE 27 Probability of death of patients by distance (km) to the hospital
Distance (km) Total number of patients Deaths Mortality rate Distribution
1–10 536 58 0.108 Beta(58,468)
11–20 93 13 0.139 Beta(13,80)
21–30 39 8 0.205 Beta(8,31)
TABLE 28 Proportion of patients by distance (km) in the different scenarios
Distance (km) General population scenario Rural population scenario Urban population scenario
1–10 0.802 0.598 0.971
11–20 0.139 0.291 0.015
> 20 0.058 0.110 0.013
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